International Flavors & Fragrances (IFF) 10-Q6 May 242024 Q1 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2024	Apr. 29, 2024
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	1-4858
Entity Registrant Name	INTERNATIONAL FLAVORS & FRAGRANCES INC
Entity Incorporation, State or Country Code	NY
Entity Tax Identification Number	13-1432060
Entity Address, Address Line One	521 West 57th Street
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10019
City Area Code	212
Local Phone Number	765-5500
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		255,350,544
Entity Central Index Key	0000051253
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Amendment Flag	false
Other Address
Entity Information [Line Items]
Entity Address, Address Line One	200 Powder Mill Road
Entity Address, City or Town	Wilmington
Entity Address, State or Province	DE
Entity Address, Postal Zip Code	19803
Common Stock, par value 12 1/2¢ per share
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, par value 12 1/2¢ per share
Trading Symbol	IFF
Security Exchange Name	NYSE
1.800% Senior Notes due 2026
Entity Information [Line Items]
Title of 12(b) Security	1.800% Senior Notes due 2026
Trading Symbol	IFF 26
Security Exchange Name	NYSE

CONSOLIDATED BALANCE SHEET

CONSOLIDATED BALANCE SHEET - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 732	$ 703
Restricted cash	7	6
Trade receivables, net	1,977	1,726
Inventories	2,411	2,477
Assets held for sale	509	506
Prepaid expenses and other current assets	771	875
Total Current Assets	6,407	6,293
Property, plant and equipment, net	4,145	4,240
Goodwill	10,538	10,635
Other intangible assets, net	8,116	8,357
Operating lease right-of-use assets	699	689
Other assets	737	764
Total Assets	30,642	30,978
Current Liabilities:
Bank borrowings, overdrafts, and current portion of long-term debt	312	885
Commercial paper	836	0
Accounts payable	1,346	1,378
Accrued payroll and bonus	222	265
Dividends payable	102	207
Liabilities held for sale	46	46
Other current liabilities	956	977
Total Current Liabilities	3,820	3,758
Long-term debt	9,150	9,186
Retirement liabilities	252	253
Deferred income taxes	1,916	1,937
Operating lease liability	651	642
Other liabilities	527	560
Total Other Liabilities	12,496	12,578
Commitments and Contingencies
Shareholders' Equity:
Common Stock, Value, Issued	35	35
Capital in excess of par value	19,889	19,874
Accumulated deficit	(2,481)	(2,439)
Accumulated other comprehensive loss	(2,191)	(1,896)
Treasury Stock, Value	(961)	(963)
Total Shareholders’ Equity	14,291	14,611
Non-controlling interests	35	31
Total Shareholders’ Equity including Non-controlling interests	14,326	14,642
Total Liabilities and Shareholders’ Equity	$ 30,642	$ 30,978
Common stock, shares issued	275,726,629	275,726,629

CONSOLIDATED BALANCE SHEET (Par

CONSOLIDATED BALANCE SHEET (Parenthetical) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Trade receivables allowances	$ 37	$ 52
Common stock, par value, in dollars per share	$ 0.125	$ 0.125
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	275,726,629	275,726,629
Common stock, shares outstanding	255,319,533	255,288,535
Treasury stock (in shares)	20,407,096	20,438,094

CONSOLIDATED STATEMENT OF INCOM

CONSOLIDATED STATEMENT OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net sales	$ 2,899	$ 3,027
Cost of goods sold	1,875	2,063
Gross profit	1,024	964
Research and development expenses	166	161
Selling and administrative expenses	490	454
Amortization of acquisition-related intangibles	168	171
Restructuring and other charges	3	52
Gain (Loss) on Disposition of Assets	2	5
Operating profit	199	131
Interest expense	83	100
Other expense, net	1	17
Income before taxes	115	14
Provision for income taxes	54	22
Net income (loss)	61	(8)
Net income attributable to non-controlling interests	1	1
Net income (loss) attributable to IFF shareholders	$ 60	$ (9)
Net income per share - basic (in dollars per share)	$ 0.23	$ (0.04)
Net income per share - diluted (in dollars per share)	$ 0.23	$ (0.04)
Average number of shares outstanding - basic (in shares)	255	255
Average number of shares outstanding - diluted (in shares)	256	255
Other comprehensive (loss) income, after tax:
Foreign currency translation adjustments	$ (293)	$ 284
Gains (losses) on derivatives qualifying as hedges; net of tax	(7)	0
Pension and postretirement liability adjustment	5	(2)
Net current period other comprehensive income (loss)	(295)	282
Comprehensive (loss) income	(234)	274
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest	1	1
Comprehensive (loss) income attributable to IFF shareholders	$ (235)	$ 273

CONSOLIDATED STATEMENT OF CASH

CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net income (loss)	$ 61	$ (8)
Adjustments to reconcile to net cash provided by operating activities
Depreciation and amortization	278	276
Deferred income taxes	(9)	(28)
Gain (Loss) on Disposition of Assets	2	5
Losses on business divestitures	0	14
Stock-based compensation	18	12
Pension contributions	(7)	(7)
Changes in assets and liabilities, net of acquisitions:
Trade receivables	(290)	(63)
Inventories	34	219
Accounts payable	83	(144)
Accruals for incentive compensation	(46)	(70)
Other current payables and accrued expenses	(28)	(51)
Other assets/liabilities, net	7	(18)
Net cash provided by operating activities	99	127
Cash flows from investing activities:
Additions to property, plant and equipment	(118)	(175)
Proceeds from disposal of assets	3	7
Net cash used in investing activities	(78)	(167)
Cash flows from financing activities:
Cash dividends paid to shareholders	(207)	(206)
Increase (decrease) in revolving credit facility and short-term borrowings	250	(100)
Net borrowings of commercial paper (maturities less than three months)	833	393
Deferred financing costs	0	(2)
Repayments of long-term debt	(833)	0
Employee withholding taxes paid	(1)	(6)
Proceeds from (Payments for) Other Financing Activities	(2)	(1)
Net cash provided by financing activities	40	78
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(25)	27
Net change in cash, cash equivalents and restricted cash	36	65
Cash, cash equivalents and restricted cash at beginning of year	735	552
Cash, cash equivalents and restricted cash at end of period	771	617
Supplemental Disclosures:
Interest paid, net of amounts capitalized	61	66
Income taxes paid, net	53	227
Accrued capital expenditures	53	71
Net proceeds received from business divestitures	$ 37	$ 1

CONSOLIDATED STATEMENT OF SHARE

CONSOLIDATED STATEMENT OF SHAREHOLDERS EQUITY - USD ($) $ in Millions	Total	Common stock	Capital in excess of par value	Retained earnings	Accumulated other comprehensive (loss) income	Treasury stock	Non-controlling interest
Shareholders' equity, beginning balance, shares at Dec. 31, 2022		275,726,629
Shareholders' equity, beginning balance at Dec. 31, 2022	$ 17,685	$ 35	$ 19,841	$ 955	$ (2,198)	$ (978)	$ 30
Treasury stock, beginning balance (in shares) at Dec. 31, 2022						20,758,166
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(8)			(9)			1
Foreign currency translation adjustments	284				284
Gains (losses) on derivatives qualifying as hedges; net of tax	0
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax	(2)				(2)
Cash dividends declared	(207)			(207)
Stock Issued During Period, Value, Stock Options Exercised	(2)		(5)			$ 3
Stock options/SSARs, shares						55,617
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	(2)		(4)			$ 2
Vested restricted stock units and awards, shares						43,396
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition	12		12
Other	(1)						(1)
Shareholders' equity, ending balance, shares at Mar. 31, 2023		275,726,629
Shareholders' equity, ending balance at Mar. 31, 2023	17,761	$ 35	19,844	739	(1,916)	$ (973)	32
Treasury stock, ending balance (in shares) at Mar. 31, 2023						20,659,153
Shareholders' equity, beginning balance, shares at Dec. 31, 2023		275,726,629
Shareholders' equity, beginning balance at Dec. 31, 2023	$ 14,642	$ 35	19,874	(2,439)	(1,896)	$ (963)	31
Treasury stock, beginning balance (in shares) at Dec. 31, 2023	20,438,094					20,438,094
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	$ 61			60			1
Foreign currency translation adjustments	(293)				(293)
Gains (losses) on derivatives qualifying as hedges; net of tax	(7)				(7)
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax	5				5
Cash dividends declared	(102)			(102)
Stock Issued During Period, Value, Stock Options Exercised	(1)		(2)			$ 1
Stock options/SSARs, shares						24,253
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	0		(1)			$ 1
Vested restricted stock units and awards, shares						6,745
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition	18		18
Other	(3)						(3)
Shareholders' equity, ending balance, shares at Mar. 31, 2024		275,726,629
Shareholders' equity, ending balance at Mar. 31, 2024	$ 14,326	$ 35	$ 19,889	$ (2,481)	$ (2,191)	$ (961)	$ 35
Treasury stock, ending balance (in shares) at Mar. 31, 2024	20,407,096					20,407,096

CONSOLIDATED STATEMENT OF SHA_2

CONSOLIDATED STATEMENT OF SHAREHOLDERS EQUITY (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Stockholders' Equity [Abstract]
Gains on derivatives qualifying as hedges; tax	$ 0
Pension liability and postretirement adjustment; tax	$ 0	$ 0
Dividends declared per share, in dollars per share	$ 0.40	$ 0.81

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Nature of Operations and Summary of Significant Accounting Policies	NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations International Flavors & Fragrances Inc. and its subsidiaries (the “Registrant,” “IFF,” “the Company,” “we,” “us” and “our”) is a leading creator and manufacturer of food, beverage, health & biosciences, scent and pharma solutions and complementary adjacent products, including cosmetic active and natural health ingredients, which are used in a wide variety of consumer products. Our products are sold principally to manufacturers of perfumes and cosmetics, hair and other personal care products, soaps and detergents, cleaning products, dairy, meat and other processed foods, beverages, snacks and savory foods, sweet and baked goods, sweeteners, dietary supplements, food protection, infant and elderly nutrition, functional food, and pharmaceutical excipients and oral care products. Basis of Presentation The accompanying interim Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and the related notes included in our 2023 Annual Report on Form 10-K (“2023 Form 10-K”), filed on February 28, 2024 with the Securities and Exchange Commission (“SEC”). The interim Consolidated Financial Statements are prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States of America for interim financial information and with the rules and regulations for reporting on Form 10-Q, and are unaudited. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP in the United States of America have been condensed or omitted, if not materially different from the 2023 Form 10-K. The year-end balance sheet data included in this Form 10-Q was derived from the audited financial statements. In the opinion of management, all adjustments, which consist of normal recurring adjustments necessary for a fair statement of the interim Consolidated Financial Statements, have been made. Correction of Prior Year Consolidated Financial Statements In the first quarter of 2024, the Company revised Interest expense from $111 million to $100 million and Other expense, net from $6 million to $17 million on its Consolidated Statements of Income (Loss) and Comprehensive (Loss) Income for the three months ended March 31, 2023. This reflects certain adjustments made to interest expense associated with the Company’s cash pooling arrangements. The Company also adjusted the disclosure of its total receivables factored for the three months ended March 31, 2023 from $445 million to $402 million. The impacts of these corrections are also presented in the related footnotes. Use of Estimates The preparation of financial statements requires management to make estimates and judgments that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. The inputs into the Company’s judgments and estimates take into account the ongoing global current events and adverse macroeconomic impacts on our critical and significant accounting estimates, including estimates associated with future cash flows that are used in assessing the risk of impairment of certain assets. Actual results could differ from those estimates. Cash, Cash Equivalents and Restricted Cash Cash, cash equivalents and restricted cash reported in the Company’s balance sheet as of March 31, 2024, December 31, 2023, March 31, 2023 and December 31, 2022 were as follows: (DOLLARS IN MILLIONS) March 31, 2024 December 31, 2023 March 31, 2023 December 31, 2022 Current assets Cash and cash equivalents $ 732 $ 703 $ 590 $ 483 Cash and cash equivalents included in Assets held for sale 32 26 4 52 Restricted cash 7 6 16 10 Non-current assets Restricted cash included in Other assets — — 7 7 Cash, cash equivalents and restricted cash $ 771 $ 735 $ 617 $ 552 Accounts Receivable The Company has various factoring agreements globally under which it can factor up to approximately $300 million of its trade receivables (“Company’s own factoring agreements”). In addition, the Company utilizes factoring agreements sponsored by certain customers. Under all of the arrangements, the Company sells the trade receivables on a non-recourse basis to unrelated financial institutions and accounts for the transactions as sales of receivables. The applicable receivables are removed from the Company’s Consolidated Balance Sheets when the cash proceeds are received by the Company. The Company sold a total of approximately $406 million and $402 million of receivables under the Company’s own factoring agreements and customer sponsored factoring agreements for the three months ended March 31, 2024 and 2023, respectively. The cost of participating in these programs was approximately $6 million and $5 million for the three months ended March 31, 2024 and 2023, respectively. These costs are included as a component of interest expense. Under the Company’s own factoring agreements for which the Company has continued responsibility to collect receivables and provide to its sponsor, it sold approximately $191 million and $197 million of receivables for the three months ended March 31, 2024 and 2023, respectively. The outstanding principal amounts of receivables under the Company’s own factoring agreements amounted to approximately $178 million and $196 million as of March 31, 2024 and December 31, 2023, respectively. The proceeds from the sales of receivables are included in Net cash provided by operating activities in the Consolidated Statements of Cash Flows. Expected Credit Losses As of March 31, 2024, the Company reported $1.977 billion of trade receivables, net of allowances of $37 million. Based on the aging analysis as of March 31, 2024, approximately 1% of the Company’s accounts receivable were past due by over 365 days based on the payment terms of the invoice. The following is a roll-forward of the Company’s allowances for bad debts for the three months ended March 31, 2024: (DOLLARS IN MILLIONS) Allowances for Balance at January 1, 2024 $ 52 Bad debt expense (reversals) (1) (5) Write-offs (9) Foreign exchange (1) Balance at March 31, 2024 $ 37 _______________________ (1) Included approximately $7 million of reversals of allowances on receivables from certain customers in Egypt. The Company will continue to evaluate its credit exposure related to Egypt. Inventories Inventories are stated at the lower of cost (on a weighted-average basis) or net realizable value. The Company’s inventories consisted of the following: (DOLLARS IN MILLIONS) March 31, 2024 December 31, 2023 Raw materials $ 728 $ 779 Work in process 432 406 Finished goods 1,251 1,292 Total $ 2,411 $ 2,477 Supply Chain Financing Program In the fourth quarter of 2023, the Company entered into a supply chain financing (“SCF”) program. The SCF program is expected to be available to U.S. based suppliers starting in the second half of 2024. The Company makes continuous efforts to improve working capital efficiency and has worked with suppliers to optimize payment terms and conditions. The Company’s current payment terms with a majority of suppliers generally range from 0 to 180 days, which is deemed to be commercially reasonable. The Company’s SCF program is voluntary and will allow its suppliers to elect to sell the receivables owed to them by the Company to a third-party financial institution. The suppliers, at their own discretion, will determine the invoices they want to sell and directly negotiate the arrangements with the participating third-party financial institution. Supplier participation in the program is solely the decision of the supplier and has no bearing on the Company’s payment terms and amounts due with the supplier. The Company’s responsibility will be limited to making payments based upon the agreed contractual terms and arrangements. The Company will not provide any form of guarantees under the SCF program and will have no economic interest in the suppliers’ decision to participate in the SCF program. Amounts due to suppliers that elect to participate in the SCF program will be included in Accounts payable on the Consolidated Balance Sheets. The Company, or the third-party financial institution, may choose to terminate the agreement of the SCF program at any time upon 30 days’ prior written notice. The third-party financial institution may also terminate the agreement of the SCF program at any time upon three business days’ prior written notice in the event there are insufficient funds available for disbursements. As of March 31, 2024 and December 31, 2023, there were no amounts outstanding related to suppliers’ participation in the SCF program. Recent Accounting Pronouncements In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” The ASU was issued to further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. This guidance is effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating the impact that this guidance will have on its income tax disclosures. In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” The ASU intends to improve reportable segment disclosure requirements, primarily through enhanced disclosures of significant segment expenses that are regularly provided to the Chief Operating Decision Maker and included within segment profit and loss. This guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted, and applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this guidance will have on its reportable segment disclosures.

Net Income Per Share

Net Income Per Share	3 Months Ended
Net Income Per Share	Mar. 31, 2024
Earnings Per Share [Abstract]
Net Income Per Share	NET INCOME (LOSS) PER SHARE A reconciliation of the shares used in the computation of basic and diluted net income (loss) per share is as follows: Three Months Ended March 31, (AMOUNTS IN MILLIONS EXCEPT PER SHARE AMOUNTS) 2024 2023 Net Income (Loss) Net income (loss) available to IFF shareholders $ 60 $ (9) Shares Weighted average common shares outstanding (basic) 255 255 Adjustment for assumed dilution: Stock options and restricted stock awards 1 — Weighted average shares assuming dilution (diluted) 256 255 Net Income (Loss) per Share Net income (loss) per share - basic (1) $ 0.23 $ (0.04) Net income (loss) per share - diluted 0.23 (0.04) _______________________ (1) For the three months ended March 31, 2024, the basic net income per share cannot be recalculated based on the information presented in the table above due to rounding. The Company declared a quarterly dividend to its shareholders of $0.40 and $0.81 per share for the three months ended March 31, 2024 and 2023, respectively. There were approximately 0.3 million potentially dilutive securities excluded from the computation of diluted net loss per share for the three months ended March 31, 2023 because there was a net loss attributable to IFF for the period and, as such, the inclusion of these securities would have been anti-dilutive. For the three months ended March 31, 2024, there were approximately 0.3 million share equivalents that had an anti-dilutive effect and therefore were excluded from the computation of diluted net income per share in the period. For the three months ended March 31, 2023, there were approximately 0.4 million share equivalents that had an anti-dilutive effect and therefore were excluded from the computation of diluted net loss per share in the period. The Company has issued shares of Purchased Restricted Stock Units (“PRSUs”) which contain rights to non-forfeitable dividends while these shares are outstanding and thus are considered participating securities. Such securities are required to be included in the computation of basic and diluted earnings per share pursuant to the two-class method. The Company did not present the two-class method since there was no difference between basic net income (loss) per share for both unrestricted common shareholders and PRSU shareholders for the three months ended March 31, 2024 and 2023. The difference between diluted net income per share for both unrestricted common shareholders and PRSU shareholders for the three months ended March 31, 2024 was less than $0.01 per share. There was no difference between diluted net loss per share for both unrestricted common shareholders and PRSU shareholders for the three months ended March 31, 2023. In addition, the number of PRSUs outstanding as of March 31, 2024 and 2023 was not material. Net income (loss) allocated to such PRSUs was not material for the three months ended March 31, 2024 and 2023.

Business Divestitures

Business Divestitures	3 Months Ended
Business Divestitures	Mar. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]
Business Divestitures	BUSINESS DIVESTITURES Liquidation of a Business in Russia As part of the liquidation of a business in Russia for the sale of the portion of the Savory Solutions business, the Company recognized a pre-tax loss of approximately $10 million presented in the Other expense, net, and tax benefits of approximately $2 million presented in Provision for income taxes on the Consolidated Statements of Income (Loss) and Comprehensive (Loss) Income for the three months ended March 31, 2023. Divestiture of the Pharma Solutions Business On March 19, 2024, the Company announced the sale process and entered into an agreement to sell its Pharma Solutions business, for a value of up to $2.85 billion, that is primarily made up of businesses within the Company’s existing Pharma Solutions reportable operating segment, with some adjustments to the perimeter of the transaction designed to align customers, businesses and the manufacturing footprint. The transaction is subject to customary closing conditions and is expected to close in the second quarter of 2025. Divestiture of the Cosmetic Ingredients Business The Company completed the divestiture of its Cosmetic Ingredients business on April 2, 2024. Upon closing, the Company received gross cash proceeds of approximately $841 million from the buyer, adjusted for the preliminary estimates of certain closing adjustments. Finalization of such closing adjustments may result in additional cash receipt from or payment to the buyer. During the third quarter of 2023, the Company announced the sale process of its Cosmetic Ingredients business within the Scent segment, and in the fourth quarter of 2023, the Company entered into an agreement to sell its Cosmetic Ingredients business. The transaction was closed on April 2, 2024. See Note 3 for additional information. The sale does not constitute a strategic shift of the Company’s operations and does not have major effects on the Company’s operations and financial results. Therefore, the transaction does not meet the discontinued operations criteria. The Company determined that the assets and liabilities of the business met the criteria to be presented as “held for sale.” As a result, as of March 31, 2024, such assets and liabilities were classified as held for sale and are reported on the Consolidated Balance Sheets. The Company expects that the sale proceeds less costs to sell will exceed the preliminary estimate of the carrying value of the net assets for the business. Included in the Company’s Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023 are the following carrying amounts of the assets and liabilities held for sale: (DOLLARS IN MILLIONS) March 31, 2024 December 31, 2023 Assets Cash and cash equivalents $ 32 $ 26 Trade receivables, net 18 15 Inventories 17 18 Property, plant and equipment, net 7 7 Goodwill 271 276 Other intangible assets, net 144 146 Operating lease right-of-use assets 10 9 Other assets 10 9 Total assets held-for-sale $ 509 $ 506 Liabilities Accounts payable $ 5 $ 4 Deferred tax liability 24 24 Other liabilities 17 18 Total liabilities held-for-sale $ 46 $ 46

Restructuring and Other Charges

Restructuring and Other Charges, Net	3 Months Ended
Restructuring and Other Charges, Net	Mar. 31, 2024
Restructuring and Related Activities [Abstract]
Restructuring and Other Charges, Net	RESTRUCTURING AND OTHER CHARGES Restructuring and other charges primarily consist of separation costs for employees including severance, outplacement and other employee benefit costs (“Severance”), charges related to the write-down of fixed assets of plants to be closed (“Fixed asset write-down”) and all other related restructuring (“Other”) costs. All restructuring and other charges are separately stated on the Consolidated Statements of Income (Loss) and Comprehensive (Loss) Income. N&B Merger Restructuring Liability For the three months ended March 31, 2024, the Company had approximately $2 million of charges related to a lease impairment. Since the inception of the restructuring activities, there have been a total of approximately 215 headcount reductions and the Company has expensed approximately $49 million. As of December 31, 2023, the restructuring activities were completed related to employee exits. The Company continues to evaluate its owned and leased properties following the combination of IFF and DuPont de Nemours, Inc’s nutrition and biosciences business (“Merger with N&B”) and may incur additional costs to further consolidate its footprint. 2023 Restructuring Program In December 2022, the Company announced a restructuring program mainly related to headcount reduction to improve its organizational and operating structure, drive efficiencies and achieve cost savings. For the three months ended March 31, 2024, the Company incurred approximately $1 million of charges related to severance. Since the inception of the restructuring program, the Company has expensed approximately $71 million and there have been a total of approximately 670 actual and planned headcount reductions. Changes in Restructuring Liabilities Changes in restructuring liabilities during the three months ended March 31, 2024 were as follows: (DOLLARS IN MILLIONS) Balance at January 1, 2024 Additional Charges (Reversals), Net Non-Cash Charges Cash Payments Balance at March 31, 2024 N&B Merger Restructuring Liability Other $ — $ 2 $ (2) $ — $ — 2023 Restructuring Program Severance 14 1 — (12) 3 Total Restructuring and other charges $ 14 $ 3 $ (2) $ (12) $ 3 Restructuring liabilities are presented in “Other current liabilities” on the Consolidated Balance Sheets. Charges by Segment The following table summarizes the total amount of costs incurred in connection with the restructuring programs and activities by segment: Three Months Ended March 31, (DOLLARS IN MILLIONS) 2024 2023 Nourish $ 2 $ 30 Health & Biosciences 1 10 Scent — 10 Pharma Solutions — 2 Total Restructuring and other charges $ 3 $ 52

Stock Compensation Plans

Stock Compensation Plans	3 Months Ended
Stock Compensation Plans	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock Compensation Plans	STOCK COMPENSATION PLANS The Company has various plans under which its officers, senior management, other key employees and directors may be granted equity-based awards. Equity awards outstanding under the plans include PRSUs, Restricted Stock Units (“RSUs”), Stock-Settled Appreciation Rights (“SSARs”) and Long-Term Incentive Plan awards. Liability-based awards outstanding under the plans are cash-settled RSUs. Stock-based compensation expense and related tax benefits were as follows: Three Months Ended March 31, (DOLLARS IN MILLIONS) 2024 2023 Equity-based awards $ 18 $ 12 Liability-based awards 1 — Total stock-based compensation expense 19 12 Less: Tax benefit (4) (2) Total stock-based compensation expense, after tax $ 15 $ 10 As of March 31, 2024, there was approximately $64 million of total unrecognized compensation cost related to non-vested awards granted under the equity incentive plans.

Segment Information

Segment Information	3 Months Ended
Segment Information	Mar. 31, 2024
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION The Company is organized into four reportable operating segments: Nourish, Health & Biosciences, Scent and Pharma Solutions. Reportable segment information was as follows: Three Months Ended March 31, (DOLLARS IN MILLIONS) 2024 2023 Net sales: Nourish $ 1,496 $ 1,653 Health & Biosciences 531 513 Scent 645 608 Pharma Solutions 227 253 Consolidated $ 2,899 $ 3,027 Segment Adjusted Operating EBITDA: Nourish $ 216 $ 208 Health & Biosciences 159 131 Scent 157 105 Pharma Solutions 46 59 Total 578 503 Depreciation & Amortization (278) (276) Interest Expense (83) (100) Other Expense, net (1) (17) Restructuring and Other Charges (a) (3) (52) Acquisition, Divestiture and Integration Related Costs (b) (58) (31) Entity Realignment Costs (c) (1) — Strategic Initiatives Costs (d) (4) (13) Regulatory Costs (e) (35) (5) Other (f) — 5 Income Before Taxes $ 115 $ 14 _______________________ (a) For 2024, represents costs related to lease impairment and severance as part of the Company's restructuring efforts. For 2023, represents costs primarily related to severance as part of the Company's restructuring efforts. (b) For 2024 and 2023, primarily represents costs related to the Company's actual and planned acquisitions and divestitures and integration related activities primarily for N&B. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts. For 2024 and 2023, tax expenses for business divestiture costs included establishments of deferred tax liabilities related to planned sales of businesses. For the three months ended March 31, 2024, business divestiture and integration related costs were approximately $56 million and $2 million, respectively. For the three months ended March 31, 2023, business divestiture and integration related costs were approximately $21 million and $10 million, respectively. (c) Represents costs related to the Company's entity realignment project to optimize the structure of holding companies, primarily consulting fees. (d) Represents costs related to the Company's strategic assessment and business portfolio optimization efforts and reorganizing the Global Business Services Centers, primarily consulting fees. (e) Represents costs primarily related to legal fees incurred and provisions recognized for the ongoing investigations of the fragrance businesses. (f) For 2024, represents the net impact of costs related to severance, including accelerated stock compensation expense, for a certain executive who has separated from the Company and gains from sale of assets. For 2023, represents gains from sale of assets. Net sales, which are attributed to individual regions based upon the destination of product delivery, were as follows: Three Months Ended March 31, (DOLLARS IN MILLIONS) 2024 2023 Europe, Africa and Middle East $ 977 $ 1,070 Greater Asia 682 688 North America 866 905 Latin America 374 364 Consolidated $ 2,899 $ 3,027 Three Months Ended March 31, (DOLLARS IN MILLIONS) 2024 2023 Net sales related to the U.S. $ 811 $ 871 Net sales attributed to all foreign countries 2,088 2,156 No non-U.S. country had net sales greater than 10% of total consolidated net sales for each of the three months ended March 31, 2024 and 2023.

Employee Benefits

Employee Benefits	3 Months Ended
Employee Benefits	Mar. 31, 2024
Retirement Benefits [Abstract]
Employee Benefits	EMPLOYEE BENEFITS Pension and other defined contribution retirement plan expenses included the following components: (DOLLARS IN MILLIONS) U.S. Plans Three Months Ended March 31, 2024 2023 Interest cost on projected benefit obligation (2) $ 6 $ 7 Expected return on plan assets (2) (6) (8) Net amortization and deferrals (2) 1 — Net periodic benefit (income) cost $ 1 $ (1) (DOLLARS IN MILLIONS) Non-U.S. Plans Three Months Ended March 31, 2024 2023 Service cost for benefits earned (1) $ 6 $ 5 Interest cost on projected benefit obligation (2) 9 9 Expected return on plan assets (2) (13) (12) Net amortization and deferrals (2) 2 — Net periodic benefit (income) cost $ 4 $ 2 _______________________ (1) Included as a component of Operating profit. (2) Included as a component of Other expense, net. The Company expects to contribute a total of $5 million to its U.S. pension plans and a total of $23 million to its non-U.S. pension plans during 2024. During the three months ended March 31, 2024, no contributions were made to the qualified U.S. pension plans, $6 million of contributions were made to the non-U.S. pension plans and $1 million of contributions were made with respect to the Company’s non-qualified U.S. pension plan. (Income) expense recognized for post-retirement benefits other than pensions included the following components: Three Months Ended March 31, (DOLLARS IN MILLIONS) 2024 2023 Interest cost on projected benefit obligation $ 1 $ 1 Net amortization and deferrals (1) (1) Total postretirement benefit (income) expense $ — $ — The Company expects to contribute $4 million to its postretirement benefits other than pension plans during 2024. In the three months ended March 31, 2024, $1 million of benefit payments were made.

Other Income and Expenses

Other Income and Expenses	3 Months Ended
Other Income and Expenses	Mar. 31, 2024
Other Income and Expenses [Abstract]
Other Expense, Net	OTHER EXPENSE, NET Other expense, net consisted of the following: Three Months Ended March 31, (DOLLARS IN MILLIONS) 2024 2023 Foreign exchange losses $ (8) $ (15) Interest income 3 — Losses on business divestitures — (14) Pension-related benefit 1 5 Other 3 7 Other expense, net $ (1) $ (17)

Income Taxes

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The effective tax rate for the three months ended March 31, 2024 was 47.0%, which was primarily driven by tax expenses relating to business divestitures and changes in the mix of earnings, some of which do not give rise to tax benefits due to valuation allowances. As of March 31, 2024, the Company had approximately $128 million of unrecognized tax benefits recorded in Other liabilities. If these unrecognized tax benefits were recognized, the effective tax rate would be affected. As of March 31, 2024, the Company had accrued interest and penalties of approximately $48 million classified in Other liabilities. As of March 31, 2024, the Company’s aggregate provisions for uncertain tax positions, including interest and penalties, was approximately $176 million associated with tax positions asserted in various jurisdictions. The Company regularly repatriates earnings from non-U.S. subsidiaries. As the Company repatriates these funds to the U.S., there will be required income taxes payable in certain U.S. states and applicable foreign withholding taxes during the period when such repatriation occurs. Accordingly, as of March 31, 2024, the Company had a deferred tax liability of approximately $174 million for the effect of repatriating the funds to the U.S., attributable to various non-U.S. subsidiaries. There is no deferred tax liability associated with non-U.S. subsidiaries where the Company intends to indefinitely reinvest the earnings to fund local operations and/or capital projects.

Property, Plant, and Equipment

Property, Plant, and Equipment	3 Months Ended
Property, Plant, and Equipment	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure	PROPERTY, PLANT AND EQUIPMENT, NET Property, plant and equipment consisted of the following amounts: (DOLLARS IN MILLIONS) March 31, 2024 December 31, 2023 Asset Type Land $ 192 $ 195 Buildings and improvements 1,805 1,822 Machinery and equipment 3,754 3,752 Information technology 496 473 Construction in process 366 400 Total Property, plant and equipment 6,613 6,642 Accumulated depreciation (2,468) (2,402) Total Property, plant and equipment, net $ 4,145 $ 4,240 Depreciation expense was $110 million and $105 million for the three months ended March 31, 2024 and 2023, respectively. Interest incurred during the construction period of certain property, plant and equipment is capitalized until the underlying assets are placed in service, at which time straight-line amortization of the capitalized interest begins over the estimated useful lives of the related assets. Capitalized interest was approximately $4 million for each of the three months ended March 31, 2024 and 2023.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets, Net Goodwill and Other Intangible Assets, Net (Notes)	3 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets, Net	GOODWILL AND OTHER INTANGIBLE ASSETS, NET Goodwill Movements in goodwill attributable to each reportable segment for the three months ended March 31, 2024 were as follows: (DOLLARS IN MILLIONS) Nourish Health & Biosciences Scent Pharma Solutions Total Balance at January 1, 2024 $ 3,489 $ 4,391 $ 1,490 $ 1,265 $ 10,635 Foreign exchange (35) (39) (8) (15) (97) Balance at March 31, 2024 $ 3,454 $ 4,352 $ 1,482 $ 1,250 $ 10,538 The goodwill balances at January 1, 2024 and March 31, 2024 included $2.623 billion and $2.250 billion of accumulated impairment related to the Nourish and Health & Biosciences reportable segments, respectively. The accumulated impairment relates to impairment charges recorded in 2023 and 2022. Other Intangible Assets Other intangible assets, net consisted of the following amounts: March 31, December 31, (DOLLARS IN MILLIONS) 2024 2023 Asset Type Customer relationships $ 8,137 $ 8,211 Technological know-how 2,336 2,355 Trade names & patents 334 337 Other 44 44 Total carrying value 10,851 10,947 Accumulated Amortization Customer relationships (1,708) (1,619) Technological know-how (863) (813) Trade names & patents (123) (117) Other (41) (41) Total accumulated amortization (2,735) (2,590) Other intangible assets, net $ 8,116 $ 8,357 Amortization Amortization expense was $168 million and $171 million for the three months ended March 31, 2024 and 2023, respectively. Amortization expense for the next five years, based on valuations and determinations of useful lives, is expected to be as follows: (DOLLARS IN MILLIONS) Remainder of 2024 2025 2026 2027 2028 Estimated future intangible amortization expense $ 502 $ 668 $ 666 $ 573 $ 559

Other Assets and Liabilities, C

Other Assets and Liabilities, Current and Noncurrent	3 Months Ended
Other Assets and Liabilities, Current and Noncurrent	Mar. 31, 2024
Other Assets [Abstract]
Other Assets and Liabilities, Current and Noncurrent	OTHER CURRENT ASSETS AND LIABILITIES, AND OTHER ASSETS Prepaid expenses and other current assets consisted of the following amounts: (DOLLARS IN MILLIONS) March 31, 2024 December 31, 2023 Value-added tax receivable $ 171 $ 187 Prepaid income taxes 163 178 Packaging materials and supplies 161 161 Prepaid expenses 202 184 Other 74 165 Total $ 771 $ 875 Other assets consisted of the following amounts: (DOLLARS IN MILLIONS) March 31, 2024 December 31, 2023 Deferred income taxes $ 253 $ 278 Overfunded pension plans 142 139 Cash surrender value of life insurance contracts 50 49 Finance lease right-of-use assets 26 26 Equity method investments 11 11 Other (1) 255 261 Total $ 737 $ 764 _______________________ (1) Includes land usage rights in China, long-term deposits and receivables on certain derivative instruments. Other current liabilities consisted of the following amounts: (DOLLARS IN MILLIONS) March 31, 2024 December 31, 2023 Rebates and incentives payable $ 102 $ 105 Value-added tax payable 49 77 Interest payable 80 65 Current pension and other postretirement benefit obligation 14 13 Accrued insurance (including workers’ compensation) 9 9 Earn outs payable 32 32 Accrued restructuring 3 14 Current operating lease obligation 91 85 Accrued freight 13 14 Accrued commissions payable 11 10 Accrued income taxes 126 194 Accrued expenses payable 300 262 Other 126 97 Total $ 956 $ 977

Debt

Debt	3 Months Ended
Debt	Mar. 31, 2024
Debt Disclosure [Abstract]
Debt	DEBT Debt consisted of the following: (DOLLARS IN MILLIONS) Effective Interest Rate March 31, 2024 December 31, 2023 2024 Euro Notes (1) 1.88 % $ — $ 552 2025 Notes (1) 1.22 % 1,000 1,000 2026 Euro Notes (1) 1.93 % 861 879 2027 Notes (1) 1.56 % 1,211 1,212 2028 Notes (1) 4.57 % 398 398 2030 Notes (1) 2.21 % 1,508 1,508 2040 Notes (1) 3.04 % 772 773 2047 Notes (1) 4.44 % 495 495 2048 Notes (1) 5.12 % 787 787 2050 Notes (1) 3.21 % 1,569 1,569 2024 Term Loan Facility (2) 3.75 % — 270 2026 Term Loan Facility (2) 5.82 % 609 625 Revolving Credit Facility (3) 250 — Commercial paper (4) 836 — Bank overdrafts and other 2 3 Total debt 10,298 10,071 Less: Short-term borrowings (5) (1,148) (885) Total Long-term debt $ 9,150 $ 9,186 _______________________ (1) Amount is net of unamortized discount and debt issuance costs. (2) Amount is recorded at fair value. (3) The interest rate on the Revolving Credit Facility is, at the applicable borrower’s option, a per annum rate equal to either (x) an eurocurrency rate plus an applicable margin varying from 1.125% to 1.750% or (y) a base rate plus an applicable margin varying from 0.125% to 0.750%, in each case depending on the public debt ratings for non-credit enhanced long-term senior unsecured debt issued by the Company. (4) The effective interest rate of commercial paper issuances fluctuates as short-term interest rates and demand fluctuate, and deferred debt issuance costs are immaterial. Additionally, the effective interest rate of commercial paper is not meaningful as issuances do not materially differ from short-term interest rates. (5) Includes bank borrowings, commercial paper, overdrafts and current portion of long-term debt. Commercial Paper For the three months ended March 31, 2024, the Company had gross issuances of $2.099 billion and repayments of $1.263 billion under the commercial paper program. The commercial paper issued had original maturities of less than 34 days. For the three months ended March 31, 2023, the Company had gross issuances of $1.320 billion and repayments of $919 million under the commercial paper program. The commercial paper issued had original maturities of less than 86 days. The commercial paper program is backed by the borrowing capacity available under the Revolving Credit Facility. The effective interest rate of commercial paper issuances does not materially differ from short-term interest rates, which fluctuate due to market conditions and as a result may impact our interest expense. Revolving Credit Facility For the three months ended March 31, 2024, the Company had drawdowns of $250 million under the Revolving Credit Facility. For the three months ended March 31, 2023, the Company had drawdowns of $400 million and repayments of $500 million under the Revolving Credit Facility. Repayments of Debt On February 1, 2024, the Company made a $270 million debt repayment related to the 2024 Term Loan Facility at maturity, which was primarily funded from commercial paper issuances. On March 14, 2024, the Company made a €500 million debt repayment related to the 2024 Euro Notes at maturity, which was primarily funded from commercial paper issuances. During the first quarter of 2024, the Company made a quarterly debt repayment of approximately $16 million related to the 2026 Term Loan Facility in accordance with the terms of the debt agreement. Subsequent Event In the first week of April 2024, the Company made net repayments totaling $586 million related to the commercial paper program and a repayment of $250 million related to the Revolving Credit Facility, which was primarily funded from the proceeds received from the divestiture of the Cosmetic Ingredients business.

Leases

Leases	3 Months Ended
Leases	Mar. 31, 2024
Leases [Abstract]
Leases	LEASES The Company has leases for corporate offices, manufacturing facilities, research and development facilities and certain transportation and office equipment. The Company’s leases have remaining lease terms of up to 50 years, some of which include options to extend the leases for up to 15 years. The components of lease expense were as follows: Three Months Ended Three Months Ended (DOLLARS IN MILLIONS) March 31, 2024 March 31, 2023 Operating leases Operating lease cost $ 32 $ 33 Variable lease cost 16 16 Total operating lease cost $ 48 $ 49 Finance leases Finance lease cost $ 3 $ 2 Supplemental cash flow information related to leases was as follows: Three Months Ended Three Months Ended (DOLLARS IN MILLIONS) March 31, 2024 March 31, 2023 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows for operating leases $ 28 $ 33 Financing cash flows for finance leases 2 2 Right-of-use assets obtained in exchange for lease obligations Operating leases 39 137 Finance leases 3 2 Operating lease right-of-use assets are presented in “Operating lease right-of-use assets” and finance lease right-of-use assets are presented in “Other assets” on the Consolidated Balance Sheets. Operating lease liabilities are presented in “Operating lease liabilities” and finance lease liabilities are presented in “Other liabilities” on the Consolidated Balance Sheets. Any other current liabilities related to operating and finance lease liabilities are presented in “Other current liabilities” on the Consolidated Balance Sheets.

Financial Instruments

Financial Instruments	3 Months Ended
Financial Instruments	Mar. 31, 2024
Investments, All Other Investments [Abstract]
Financial Instruments	FINANCIAL INSTRUMENTS Fair Value Accounting guidance on fair value measurements specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs create the following fair value hierarchy: • Level 1 — Quoted prices for identical instruments in active markets. • Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. • Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable . This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The Company also considers counterparty credit risk in its assessment of fair value. The Company determines the fair value of structured liabilities (where performance is linked to structured interest rates, inflation or currency risks) using the Secured Overnight Financing Rate (“Term SOFR”) swap curve and forward interest and exchange rates at period end. Such instruments are classified as Level 2 based on the observability of significant inputs to the model. The Company does not have any instruments classified as Level 3, other than those included in pension asset trusts as discussed in Note 15 of the Company’s 2023 Form 10-K. The carrying values and the estimated fair values of financial instruments at March 31, 2024 and December 31, 2023 consisted of the following: March 31, 2024 December 31, 2023 (DOLLARS IN MILLIONS) Carrying Value Fair Value Carrying Value Fair Value LEVEL 1 Cash and cash equivalents (1) $ 732 $ 732 $ 703 $ 703 LEVEL 2 Credit facilities and bank overdrafts (2) 252 252 3 3 Derivatives Derivative assets (3) 1 1 41 41 Derivative liabilities (3) 166 166 165 165 Commercial paper (2) 836 836 — — Long-term debt: 2024 Euro Notes (4) — — 552 549 2025 Notes (4) 1,000 937 1,000 924 2026 Euro Notes (4) 861 825 879 835 2027 Notes (4) 1,211 1,066 1,212 1,049 2028 Notes (4) 398 388 398 389 2030 Notes (4) 1,508 1,248 1,508 1,240 2040 Notes (4) 772 535 773 536 2047 Notes (4) 495 389 495 382 2048 Notes (4) 787 687 787 678 2050 Notes (4) 1,569 1,002 1,569 1,029 2024 Term Loan Facility (5) — — 270 270 2026 Term Loan Facility (5) 609 609 625 625 _______________________ (1) The carrying amount of cash and cash equivalents approximates fair value due to the short maturity of those instruments. (2) The carrying amount approximates fair value as the interest rate is reset frequently based on current market rates as well as the short maturity of those instruments. (3) The carrying amount approximates fair value as the instruments are marked-to-market and held at fair value on the Consolidated Balance Sheets. (4) The fair value of the Note is obtained from pricing services engaged by the Company, and the Company receives one price for each security. The fair value provided by the pricing services are estimated using pricing models, where the inputs to those models are based on observable market inputs or recent trades of similar securities. The inputs to the valuation techniques applied by the pricing services are typically benchmark yields, benchmark security prices, credit spreads, reported trades and broker-dealer quotes, all with reasonable levels of transparency. (5) The carrying amount approximates fair value as the Term Loans were assumed at fair value and the interest rate is reset frequently based on current market rates. Derivatives Foreign Currency Forward Contracts The Company periodically enters into foreign currency forward contracts with the objective of managing our exchange rate risk related to foreign currency denominated monetary assets and liabilities of our operations. These contracts generally involve the exchange of one currency for a second currency at a future date, have maturities not exceeding twelve months and are with counterparties which are major international financial institutions. Commodity Contracts The Company utilizes options, futures and swaps that are not designated as hedging instruments to reduce exposure to commodity price fluctuations on purchases of inventory such as soybeans, soybean oil and soybean meal. The Company also utilizes options, futures and swaps that are designated as hedging instruments to reduce exposure to commodity price fluctuations on purchases of natural gas used in our manufacturing process. Hedges Related to Issuances of Debt As of March 31, 2024, the Company designated approximately $861 million of Euro Notes as a hedge of a portion of its net European investments. Accordingly, the change in the value of the debt that is attributable to foreign exchange movements is recorded in Other comprehensive income (“OCI”) as a component of foreign currency translation adjustments in the accompanying Consolidated Statements of Income (Loss) and Comprehensive (Loss) Income. Cross Currency Swaps The Company has twelve EUR/USD cross currency swaps with a notional value of $1.400 billion that mature through November 2030. The swaps all qualified as net investment hedges in order to mitigate a portion of the Company’s net European investments from foreign currency risk. As of March 31, 2024, the twelve swaps were in a liability position with an aggregate fair value of $132 million, which were classified as Other liabilities on the Consolidated Balance Sheets. Changes in fair value related to cross currency swaps are recorded in OCI. The following table shows the notional amount of the Company’s derivative instruments outstanding as of March 31, 2024 and December 31, 2023: (DOLLARS IN MILLIONS) March 31, 2024 December 31, 2023 Foreign currency contracts (1) $ (2,697) $ (1,400) Commodity contracts (1) 6 7 Cross currency swaps 1,400 1,400 _______________________ (1) Foreign currency contracts and commodity contracts are presented net of contracts bought and sold. The following tables show the Company’s derivative instruments measured at fair value (Level 2 of the fair value hierarchy), as reflected on the Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023: March 31, 2024 (DOLLARS IN MILLIONS) Fair Value of Fair Value of Total Fair Value Derivative assets (1) Foreign currency contracts $ — $ 1 $ 1 Total derivative assets $ — $ 1 $ 1 Derivative liabilities (2) Foreign currency contracts $ — $ 33 $ 33 Cross currency swaps 132 — 132 Commodity contracts 1 — 1 Total derivative liabilities $ 133 $ 33 $ 166 December 31, 2023 (DOLLARS IN MILLIONS) Fair Value of Fair Value of Total Fair Value Derivative assets (1) Foreign currency contracts $ — $ 41 $ 41 Total derivative assets $ — $ 41 $ 41 Derivative liabilities (2) Foreign currency contracts $ — $ 4 $ 4 Cross currency swaps 161 — 161 Total derivative liabilities $ 161 $ 4 $ 165 _______________________ (1) Derivative assets are recorded to Prepaid expenses and other current assets on the Consolidated Balance Sheets. (2) Derivative liabilities are recorded to Other current liabilities and Other liabilities on the Consolidated Balance Sheets. The following table shows the effect of the Company’s derivative instruments which were not designated as hedging instruments on the Consolidated Statements of Income (Loss) and Comprehensive (Loss) Income for the three months ended March 31, 2024 and 2023: Amount of Gain (Loss) Location of Gain (Loss) Recognized in Income on Derivative (DOLLARS IN MILLIONS) Three Months Ended March 31, 2024 2023 Foreign currency contracts (1) $ (3) $ — Other expense, net _______________________ (1) The foreign currency contract net gains (losses) offset any recognized gains (losses) arising from the revaluation of the related intercompany loans during the same respective periods. The following table shows the effect of the Company’s derivative and non-derivative instruments designated as cash flow and net investment hedging instruments, net of tax, on the Consolidated Statements of Income (Loss) and Comprehensive (Loss) Income for the three months ended March 31, 2024 and 2023: Amount of Gain (Loss) Location of Gain (Loss) Amount of Gain (Loss) Three Months Ended March 31, Three Months Ended March 31, (DOLLARS IN MILLIONS) 2024 2023 2024 2023 Derivatives in Cash Flow Hedging Relationships: Foreign currency contracts $ (7) $ — N/A $ — $ — Derivatives in Net Investment Hedging Relationships: Cross currency swaps 23 (3) N/A — — Non-Derivatives in Net Investment Hedging Relationships: 2024 Euro Notes 3 (9) N/A — — 2026 Euro Notes 15 (14) N/A — — Total $ 34 $ (26) $ — $ — The ineffective portion of the above noted net investment hedges was approximately $4 million for each of the three months ended March 31, 2024 and 2023, and was recorded as a reduction to Interest expense on the Consolidated Statements of Income (Loss) and Comprehensive (Loss) Income. At March 31, 2024, based on current market rates, the Company does not expect any material derivative losses (net of tax), included in AOCI, to be reclassified into earnings within the next 12 months.

Discontinued Operations and Dis

Discontinued Operations and Disposal Groups	3 Months Ended
Discontinued Operations and Disposal Groups	Mar. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]
Assets and Liabilities Held For Sale	BUSINESS DIVESTITURES Liquidation of a Business in Russia As part of the liquidation of a business in Russia for the sale of the portion of the Savory Solutions business, the Company recognized a pre-tax loss of approximately $10 million presented in the Other expense, net, and tax benefits of approximately $2 million presented in Provision for income taxes on the Consolidated Statements of Income (Loss) and Comprehensive (Loss) Income for the three months ended March 31, 2023. Divestiture of the Pharma Solutions Business On March 19, 2024, the Company announced the sale process and entered into an agreement to sell its Pharma Solutions business, for a value of up to $2.85 billion, that is primarily made up of businesses within the Company’s existing Pharma Solutions reportable operating segment, with some adjustments to the perimeter of the transaction designed to align customers, businesses and the manufacturing footprint. The transaction is subject to customary closing conditions and is expected to close in the second quarter of 2025. Divestiture of the Cosmetic Ingredients Business The Company completed the divestiture of its Cosmetic Ingredients business on April 2, 2024. Upon closing, the Company received gross cash proceeds of approximately $841 million from the buyer, adjusted for the preliminary estimates of certain closing adjustments. Finalization of such closing adjustments may result in additional cash receipt from or payment to the buyer. During the third quarter of 2023, the Company announced the sale process of its Cosmetic Ingredients business within the Scent segment, and in the fourth quarter of 2023, the Company entered into an agreement to sell its Cosmetic Ingredients business. The transaction was closed on April 2, 2024. See Note 3 for additional information. The sale does not constitute a strategic shift of the Company’s operations and does not have major effects on the Company’s operations and financial results. Therefore, the transaction does not meet the discontinued operations criteria. The Company determined that the assets and liabilities of the business met the criteria to be presented as “held for sale.” As a result, as of March 31, 2024, such assets and liabilities were classified as held for sale and are reported on the Consolidated Balance Sheets. The Company expects that the sale proceeds less costs to sell will exceed the preliminary estimate of the carrying value of the net assets for the business. Included in the Company’s Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023 are the following carrying amounts of the assets and liabilities held for sale: (DOLLARS IN MILLIONS) March 31, 2024 December 31, 2023 Assets Cash and cash equivalents $ 32 $ 26 Trade receivables, net 18 15 Inventories 17 18 Property, plant and equipment, net 7 7 Goodwill 271 276 Other intangible assets, net 144 146 Operating lease right-of-use assets 10 9 Other assets 10 9 Total assets held-for-sale $ 509 $ 506 Liabilities Accounts payable $ 5 $ 4 Deferred tax liability 24 24 Other liabilities 17 18 Total liabilities held-for-sale $ 46 $ 46

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	3 Months Ended
Accumulated Other Comprehensive Income (Loss)	Mar. 31, 2024
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss)	ACCUMULATED OTHER COMPREHENSIVE LOSS The following tables present changes in the accumulated balances for each component of other comprehensive (loss) income, including current period other comprehensive (loss) income and reclassifications out of accumulated other comprehensive loss: (DOLLARS IN MILLIONS) Foreign Gains (Losses) Pension and Total Accumulated other comprehensive (loss) income, net of tax, as of January 1, 2024 $ (1,652) $ 1 $ (245) $ (1,896) OCI before reclassifications (293) (7) 3 (297) Amounts reclassified from AOCI — — 2 2 Net current period other comprehensive income (loss) (293) (7) 5 (295) Accumulated other comprehensive (loss) income, net of tax, as of March 31, 2024 $ (1,945) $ (6) $ (240) $ (2,191) (DOLLARS IN MILLIONS) Foreign Gains (Losses) Pension and Total Accumulated other comprehensive (loss) income, net of tax, as of January 1, 2023 $ (2,066) $ 1 $ (133) $ (2,198) OCI before reclassifications 284 — (1) 283 Amounts reclassified from AOCI — — (1) (1) Net current period other comprehensive income (loss) 284 — (2) 282 Accumulated other comprehensive (loss) income, net of tax, as of March 31, 2023 $ (1,782) $ 1 $ (135) $ (1,916) The following table provides details about reclassifications out of Accumulated other comprehensive loss to the Consolidated Statements of Income (Loss) and Comprehensive (Loss) Income: Three Months Ended March 31, Affected Line Item in the Consolidated Statements of Income (Loss) and Comprehensive (Loss) Income (DOLLARS IN MILLIONS) 2024 2023 Gains (losses) on pension and postretirement liability adjustments Prior service cost $ 1 $ 1 (1) Actuarial losses (3) — (1) Tax — — Provision for income taxes Total $ (2) $ 1 Total, net of income taxes _______________________ (1) The amortization of prior service cost and actuarial loss is included in the computation of net periodic benefit cost. Refer to Note 15 of the Company’s 2023 Form 10-K for additional information regarding net periodic benefit cost.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES Guarantees and Letters of Credit The Company has various bank guarantees, letters of credit and surety bonds which are used to support its ongoing business operations, satisfy governmental requirements associated with pending litigation in various jurisdictions and the payment of customs duties. As of March 31, 2024, the Company had a total of approximately $226 million of bank guarantees, commercial guarantees, standby letters of credit and surety bonds with various financial institutions. Included in the above aggregate amount was a total of approximately $10 million for other assessments in Brazil for various income tax and indirect tax disputes related to fiscal years 1998-2011. There was a total of approximately $60 million outstanding under the bank guarantees, standby letters of credit and commercial guarantees as of March 31, 2024. In order to challenge the assessments in these cases in Brazil, the Company has been required to, and has separately pledged assets, principally property, plant and equipment, to cover assessments in the amount of approximately $8 million as of March 31, 2024. Lines of Credit The Company has various lines of credit which are available to support its ongoing business operations. As of March 31, 2024, the Company had a total capacity of approximately $1.860 billion of lines of credit with various financial institutions, in addition to the $1.791 billion of capacity under the Revolving Credit Facility. Pursuant to these lines of credit as of March 31, 2024, there were total drawdowns of approximately $1.089 billion primarily related to the issuances of commercial paper and borrowings under the Revolving Credit Facility for approximately $836 million and $250 million, respectively. See Note 13 for additional information. Litigation The Company assesses contingencies related to litigation and/or other matters to determine the degree of probability and range of possible loss. A loss contingency is accrued in the Company’s Consolidated Financial Statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing contingencies is highly sensitive and requires judgments about future events. On at least a quarterly basis, the Company reviews contingencies related to litigation to determine the adequacy of accruals. The amount of ultimate loss may differ from these estimates and further events may require the Company to increase or decrease the amounts it has accrued on any matter. Periodically, the Company assesses its insurance coverage for all known claims, where applicable, taking into account aggregate coverage by occurrence, limits of coverage, self-insured retentions and deductibles, historical claims experience and claims experience with its insurance carriers. The liabilities are recorded at management’s best estimate of the probable outcome of the lawsuits and claims, taking into consideration the facts and circumstances of the individual matters as well as past experience on similar matters. At each balance sheet date, the key issues that management assesses are whether it is probable that a loss as to asserted or unasserted claims has been incurred and if so, whether the amount of loss can be reasonably estimated. The Company records the expected liability with respect to claims in Other liabilities and expected recoveries from its insurance carriers in Other assets. The Company recognizes a receivable when it believes that realization of the insurance receivable is probable under the terms of the insurance policies and its payment experience to date. Litigation Matters Two motions to approve securities class actions were filed in the Tel Aviv District Court, Israel, in August 2019, alleging, among other things, false and misleading statements largely in connection with IFF’s acquisition of Frutarom and improper payments made by Frutarom businesses operating principally in Russia and Ukraine to representatives of customers. One motion (“Borg”) asserted claims under the U.S. federal securities laws against IFF, its former Chairman and CEO, and its former CFO. The Borg case is now dismissed. The other motion (“Oman”) (following an initial amendment) asserted claims under the Israeli Securities Act-1968 against IFF, its former Chairman and CEO, and its former CFO, and against Frutarom and certain former Frutarom officers and directors, as well as claims under the Israeli Companies Act-1999 against certain former Frutarom officers and directors. On July 14, 2022, the court approved the parties’ motion to mediate the dispute, which postpones all case deadlines until after the mediation. The parties held mediation meetings on September 13, 2022, November 22, 2022, March 1, 2023, November 2023, March 3, 2024 and April 1, 2024. On October 29, 2019, IFF and Frutarom filed a claim in the Tel Aviv District Court, Israel, against Ori Yehudai, the former President and CEO of Frutarom, and against certain former directors of Frutarom, challenging the bonus of US $20 million granted to Yehudai in 2018. IFF and Frutarom allege, among other things, that Yehudai was not entitled to receive the bonus because he breached his fiduciary duty by, among other things, knowing of the above-mentioned improper payments and failing to prevent them from being made. The parties agreed, pursuant to the court’s recommendation, to attempt to resolve the dispute through mediation, and a court decision is pending with regard to the order in which this claim and the class action described below will be heard. On March 11, 2020, an IFF shareholder filed a motion to approve a class action in Israel against, among others, Frutarom, Yehudai, and Frutarom’s former board of directors, alleging that former minority shareholders of Frutarom were harmed as a result of the US $20 million bonus paid to Yehudai. The court held an evidentiary hearing on the motion to approve a class action in March 2024. Since March 2023, various putative class action lawsuits have been filed against IFF, Firmenich International SA, Givaudan SA, and Symrise AG and/or certain affiliates thereof in the Quebec Superior Court, the Federal Court of Canada, Ontario Superior Court, the Supreme Court of British Columbia and, in several cases, the United States District Court for the District of New Jersey. These actions allege violations of the Canadian Competition Act and the Sherman Act, as applicable, and other related claims, and seek damages and other relief. In December 2023, the Federal Court of Canada proceeding was discontinued in its entirety. IFF may face additional civil suits, in the United States or elsewhere, relating to such alleged conduct. At this time, IFF is unable to predict the potential outcome of these lawsuits or any potential effect they may have on the Company’s results of operations, liquidity or financial condition. Investigations On June 3, 2020, the Israel Police’s National Fraud Investigation Unit and the Israeli Securities Authority commenced an investigation into Frutarom and certain of its former executives, based on suspected bribery of foreign officials, money laundering, and violations of the Israeli Securities Act-1968. On February 26, 2024, the Israeli authorities informed Frutarom that the authorities decided to close the criminal investigation. On March 7, 2023, the European Commission (“EC”) and the United Kingdom Competition and Markets Authority (“CMA”) carried out unannounced inspections of certain of IFF’s facilities. On the same day, IFF was served with a grand jury subpoena by the Antitrust Division of the U.S. Department of Justice (“DOJ”). IFF understands the EC, CMA, DOJ and the Swiss Competition Commission are investigating potential anticompetitive conduct as it relates to IFF’s fragrance businesses. IFF has been and intends to continue cooperating with these investigations. During the first quarter of 2024, IFF has recognized a provision related to a procedural aspect of the investigation, which was not material to the financial statements. IFF is currently unable, however, to predict or determine the duration or outcome of the investigations, or whether the outcome of the investigations will materially impact the Company’s results of operations, liquidity or financial condition. Additionally, the Company from time to time does receive complaints from customers regarding product quality, performance or other aspects of its ongoing relationships. The Company is unable to determine whether the potential settlement of customer claims, if any, will materially impact the Company’s results of operations, liquidity or financial condition. Environmental Proceedings The Company is reporting the following environmental matter in compliance with SEC requirements to disclose environmental proceedings where a governmental authority is a party and that involve potential monetary sanctions of $300,000 or greater. Effective March 22, 2024, the Solae, LLC Memphis site (“Solae”) signed an Administrative Order on Consent (the “Consent Order”) resolving violations and penalties pertaining to the Administrative Order and Assessment received from the City of Memphis on May 27, 2022 related to alleged wastewater discharge violations. In view of the Consent Order, Solae withdrew its previously filed appeal. Pursuant to the Consent Order, Solae is completing its capital project efforts in accordance with the agreed schedule for attaining compliance with current wastewater permit requirements. This matter is not expected to have a material adverse effect on the Company’s financial position, cash flows or results of operations. Other Contingencies The Company has contingencies involving third parties (such as labor, contract, technology or product-related claims or litigation) as well as government-related items in various jurisdictions in which it operates pertaining to such items as value-added taxes, other indirect taxes, customs and duties and sales and use taxes. It is possible that cash flows or results of operations, in any period, could be materially affected by the unfavorable resolution of one or more of these contingencies. The most significant government-related contingencies exist in Brazil. With regard to the Brazilian matters, the Company believes it has valid defenses for the underlying positions under dispute; however, in order to pursue these defenses, the Company is required to, and has provided, bank guarantees and pledged assets in the aggregate amount of approximately $18 million. The Brazilian matters take an extended period of time to proceed through the judicial process and there are a limited number of rulings to date. Other The Company is subject to various legal proceedings and claims that have arisen in the ordinary course of business and have not been fully resolved. Due to the inherent subjectivity and unpredictability of outcomes of legal proceedings, the Company is unable to determine, with certainty, the probability of the outcome of these matters or the range of reasonably possible losses, if any.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Millions	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net Income (Loss) Attributable to Parent	$ 60	$ (9)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Mar. 31, 2024
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	During the quarter ended March 31, 2024, none of our directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (a “10b5-1 trading arrangement”) or any “non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K.
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations International Flavors & Fragrances Inc. and its subsidiaries (the “Registrant,” “IFF,” “the Company,” “we,” “us” and “our”) is a leading creator and manufacturer of food, beverage, health & biosciences, scent and pharma solutions and complementary adjacent products, including cosmetic active and natural health ingredients, which are used in a wide variety of consumer products. Our products are sold principally to manufacturers of perfumes and cosmetics, hair and other personal care products, soaps and detergents, cleaning products, dairy, meat and other processed foods, beverages, snacks and savory foods, sweet and baked goods, sweeteners, dietary supplements, food protection, infant and elderly nutrition, functional food, and pharmaceutical excipients and oral care products.
Basis of Presentation	Basis of Presentation The accompanying interim Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and the related notes included in our 2023 Annual Report on Form 10-K (“2023 Form 10-K”), filed on February 28, 2024 with the Securities and Exchange Commission (“SEC”). The interim Consolidated Financial Statements are prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States of America for interim financial information and with the rules and regulations for reporting on Form 10-Q, and are unaudited. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP in the United States of America have been condensed or omitted, if not materially different from the 2023 Form 10-K. The year-end balance sheet data included in this Form 10-Q was derived from the audited financial statements. In the opinion of management, all adjustments, which consist of normal recurring adjustments necessary for a fair statement of the interim Consolidated Financial Statements, have been made.
Use of Estimates	Use of Estimates The preparation of financial statements requires management to make estimates and judgments that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. The inputs into the Company’s judgments and estimates take into account the ongoing global current events and adverse macroeconomic impacts on our critical and significant accounting estimates, including estimates associated with future cash flows that are used in assessing the risk of impairment of certain assets. Actual results could differ from those estimates.
Accounts Receivable	Accounts Receivable The Company has various factoring agreements globally under which it can factor up to approximately $300 million of its trade receivables (“Company’s own factoring agreements”). In addition, the Company utilizes factoring agreements sponsored by certain customers. Under all of the arrangements, the Company sells the trade receivables on a non-recourse basis to unrelated financial institutions and accounts for the transactions as sales of receivables. The applicable receivables are removed from the Company’s Consolidated Balance Sheets when the cash proceeds are received by the Company. The Company sold a total of approximately $406 million and $402 million of receivables under the Company’s own factoring agreements and customer sponsored factoring agreements for the three months ended March 31, 2024 and 2023, respectively. The cost of participating in these programs was approximately $6 million and $5 million for the three months ended March 31, 2024 and 2023, respectively. These costs are included as a component of interest expense. Under the Company’s own factoring agreements for which the Company has continued responsibility to collect receivables and provide to its sponsor, it sold approximately $191 million and $197 million of receivables for the three months ended March 31, 2024 and 2023, respectively. The outstanding principal amounts of receivables under the Company’s own factoring agreements amounted to approximately $178 million and $196 million as of March 31, 2024 and December 31, 2023, respectively. The proceeds from the sales of receivables are included in Net cash provided by operating activities in the Consolidated Statements of Cash Flows.
Expected Credit Loss	Expected Credit Losses As of March 31, 2024, the Company reported $1.977 billion of trade receivables, net of allowances of $37 million. Based on the aging analysis as of March 31, 2024, approximately 1% of the Company’s accounts receivable were past due by over 365 days based on the payment terms of the invoice.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” The ASU was issued to further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. This guidance is effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating the impact that this guidance will have on its income tax disclosures. In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” The ASU intends to improve reportable segment disclosure requirements, primarily through enhanced disclosures of significant segment expenses that are regularly provided to the Chief Operating Decision Maker and included within segment profit and loss. This guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted, and applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this guidance will have on its reportable segment disclosures.
Inventory, Policy	Inventories
Supplier Finance Program, Policy	Supply Chain Financing Program In the fourth quarter of 2023, the Company entered into a supply chain financing (“SCF”) program. The SCF program is expected to be available to U.S. based suppliers starting in the second half of 2024. The Company makes continuous efforts to improve working capital efficiency and has worked with suppliers to optimize payment terms and conditions. The Company’s current payment terms with a majority of suppliers generally range from 0 to 180 days, which is deemed to be commercially reasonable. The Company’s SCF program is voluntary and will allow its suppliers to elect to sell the receivables owed to them by the Company to a third-party financial institution. The suppliers, at their own discretion, will determine the invoices they want to sell and directly negotiate the arrangements with the participating third-party financial institution. Supplier participation in the program is solely the decision of the supplier and has no bearing on the Company’s payment terms and amounts due with the supplier. The Company’s responsibility will be limited to making payments based upon the agreed contractual terms and arrangements. The Company will not provide any form of guarantees under the SCF program and will have no economic interest in the suppliers’ decision to participate in the SCF program. Amounts due to suppliers that elect to participate in the SCF program will be included in Accounts payable on the Consolidated Balance Sheets. The Company, or the third-party financial institution, may choose to terminate the agreement of the SCF program at any time upon 30 days’ prior written notice. The third-party financial institution may also terminate the agreement of the SCF program at any time upon three business days’ prior written notice in the event there are insufficient funds available for disbursements. As of March 31, 2024 and December 31, 2023, there were no amounts outstanding related to suppliers’ participation in the SCF program.

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Reconciliation of Cash	Cash, cash equivalents and restricted cash reported in the Company’s balance sheet as of March 31, 2024, December 31, 2023, March 31, 2023 and December 31, 2022 were as follows: (DOLLARS IN MILLIONS) March 31, 2024 December 31, 2023 March 31, 2023 December 31, 2022 Current assets Cash and cash equivalents $ 732 $ 703 $ 590 $ 483 Cash and cash equivalents included in Assets held for sale 32 26 4 52 Restricted cash 7 6 16 10 Non-current assets Restricted cash included in Other assets — — 7 7 Cash, cash equivalents and restricted cash $ 771 $ 735 $ 617 $ 552
Schedule of Bad Debt Reserve	The following is a roll-forward of the Company’s allowances for bad debts for the three months ended March 31, 2024: (DOLLARS IN MILLIONS) Allowances for Balance at January 1, 2024 $ 52 Bad debt expense (reversals) (1) (5) Write-offs (9) Foreign exchange (1) Balance at March 31, 2024 $ 37 _______________________ (1) Included approximately $7 million of reversals of allowances on receivables from certain customers in Egypt. The Company will continue to evaluate its credit exposure related to Egypt.
Schedule of Inventory, Current	The Company’s inventories consisted of the following: (DOLLARS IN MILLIONS) March 31, 2024 December 31, 2023 Raw materials $ 728 $ 779 Work in process 432 406 Finished goods 1,251 1,292 Total $ 2,411 $ 2,477

Net Income Per Share (Tables)

Net Income Per Share (Tables)	3 Months Ended
Net Income Per Share (Tables)	Mar. 31, 2024
Earnings Per Share [Abstract]
Reconciliation of Shares Used in Computation of Basic and Diluted Net Income Per Share	A reconciliation of the shares used in the computation of basic and diluted net income (loss) per share is as follows: Three Months Ended March 31, (AMOUNTS IN MILLIONS EXCEPT PER SHARE AMOUNTS) 2024 2023 Net Income (Loss) Net income (loss) available to IFF shareholders $ 60 $ (9) Shares Weighted average common shares outstanding (basic) 255 255 Adjustment for assumed dilution: Stock options and restricted stock awards 1 — Weighted average shares assuming dilution (diluted) 256 255 Net Income (Loss) per Share Net income (loss) per share - basic (1) $ 0.23 $ (0.04) Net income (loss) per share - diluted 0.23 (0.04) _______________________ (1) For the three months ended March 31, 2024, the basic net income per share cannot be recalculated based on the information presented in the table above due to rounding.

Restructuring and Other Charg_2

Restructuring and Other Charges, Net (Tables)	3 Months Ended
Restructuring and Other Charges, Net (Tables)	Mar. 31, 2024
Restructuring and Related Activities [Abstract]
Changes in Employee-Related Restructuring Liabilities	Changes in Restructuring Liabilities Changes in restructuring liabilities during the three months ended March 31, 2024 were as follows: (DOLLARS IN MILLIONS) Balance at January 1, 2024 Additional Charges (Reversals), Net Non-Cash Charges Cash Payments Balance at March 31, 2024 N&B Merger Restructuring Liability Other $ — $ 2 $ (2) $ — $ — 2023 Restructuring Program Severance 14 1 — (12) 3 Total Restructuring and other charges $ 14 $ 3 $ (2) $ (12) $ 3 Restructuring liabilities are presented in “Other current liabilities” on the Consolidated Balance Sheets. Charges by Segment The following table summarizes the total amount of costs incurred in connection with the restructuring programs and activities by segment: Three Months Ended March 31, (DOLLARS IN MILLIONS) 2024 2023 Nourish $ 2 $ 30 Health & Biosciences 1 10 Scent — 10 Pharma Solutions — 2 Total Restructuring and other charges $ 3 $ 52

Stock Compensation Plans (Table

Stock Compensation Plans (Tables)	3 Months Ended
Stock Compensation Plans (Tables)	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation Expense and Related Tax Benefits	Stock-based compensation expense and related tax benefits were as follows: Three Months Ended March 31, (DOLLARS IN MILLIONS) 2024 2023 Equity-based awards $ 18 $ 12 Liability-based awards 1 — Total stock-based compensation expense 19 12 Less: Tax benefit (4) (2) Total stock-based compensation expense, after tax $ 15 $ 10 As of March 31, 2024, there was approximately $64 million of total unrecognized compensation cost related to non-vested awards granted under the equity incentive plans.

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
Segment Information (Tables)	Mar. 31, 2024
Segment Reporting [Abstract]
Reportable Segment Information	Reportable segment information was as follows: Three Months Ended March 31, (DOLLARS IN MILLIONS) 2024 2023 Net sales: Nourish $ 1,496 $ 1,653 Health & Biosciences 531 513 Scent 645 608 Pharma Solutions 227 253 Consolidated $ 2,899 $ 3,027 Segment Adjusted Operating EBITDA: Nourish $ 216 $ 208 Health & Biosciences 159 131 Scent 157 105 Pharma Solutions 46 59 Total 578 503 Depreciation & Amortization (278) (276) Interest Expense (83) (100) Other Expense, net (1) (17) Restructuring and Other Charges (a) (3) (52) Acquisition, Divestiture and Integration Related Costs (b) (58) (31) Entity Realignment Costs (c) (1) — Strategic Initiatives Costs (d) (4) (13) Regulatory Costs (e) (35) (5) Other (f) — 5 Income Before Taxes $ 115 $ 14 _______________________ (a) For 2024, represents costs related to lease impairment and severance as part of the Company's restructuring efforts. For 2023, represents costs primarily related to severance as part of the Company's restructuring efforts. (b) For 2024 and 2023, primarily represents costs related to the Company's actual and planned acquisitions and divestitures and integration related activities primarily for N&B. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts. For 2024 and 2023, tax expenses for business divestiture costs included establishments of deferred tax liabilities related to planned sales of businesses. For the three months ended March 31, 2024, business divestiture and integration related costs were approximately $56 million and $2 million, respectively. For the three months ended March 31, 2023, business divestiture and integration related costs were approximately $21 million and $10 million, respectively. (c) Represents costs related to the Company's entity realignment project to optimize the structure of holding companies, primarily consulting fees. (d) Represents costs related to the Company's strategic assessment and business portfolio optimization efforts and reorganizing the Global Business Services Centers, primarily consulting fees. (e) Represents costs primarily related to legal fees incurred and provisions recognized for the ongoing investigations of the fragrance businesses. (f) For 2024, represents the net impact of costs related to severance, including accelerated stock compensation expense, for a certain executive who has separated from the Company and gains from sale of assets. For 2023, represents gains from sale of assets.
Net Sales by Destination of Product Delivery	Net sales, which are attributed to individual regions based upon the destination of product delivery, were as follows: Three Months Ended March 31, (DOLLARS IN MILLIONS) 2024 2023 Europe, Africa and Middle East $ 977 $ 1,070 Greater Asia 682 688 North America 866 905 Latin America 374 364 Consolidated $ 2,899 $ 3,027 Three Months Ended March 31, (DOLLARS IN MILLIONS) 2024 2023 Net sales related to the U.S. $ 811 $ 871 Net sales attributed to all foreign countries 2,088 2,156

Employee Benefits (Tables)

Employee Benefits (Tables)	3 Months Ended
Employee Benefits (Tables)	Mar. 31, 2024
Retirement Benefits [Abstract]
Pension and Other Defined Contribution Retirement Plan Expenses	Pension and other defined contribution retirement plan expenses included the following components: (DOLLARS IN MILLIONS) U.S. Plans Three Months Ended March 31, 2024 2023 Interest cost on projected benefit obligation (2) $ 6 $ 7 Expected return on plan assets (2) (6) (8) Net amortization and deferrals (2) 1 — Net periodic benefit (income) cost $ 1 $ (1) (DOLLARS IN MILLIONS) Non-U.S. Plans Three Months Ended March 31, 2024 2023 Service cost for benefits earned (1) $ 6 $ 5 Interest cost on projected benefit obligation (2) 9 9 Expected return on plan assets (2) (13) (12) Net amortization and deferrals (2) 2 — Net periodic benefit (income) cost $ 4 $ 2 _______________________ (1) Included as a component of Operating profit. (2) Included as a component of Other expense, net.
Postretirement Benefits Other Than Pension Expenses	(Income) expense recognized for post-retirement benefits other than pensions included the following components: Three Months Ended March 31, (DOLLARS IN MILLIONS) 2024 2023 Interest cost on projected benefit obligation $ 1 $ 1 Net amortization and deferrals (1) (1) Total postretirement benefit (income) expense $ — $ —

Other Expense, Net (Tables)

Other Expense, Net (Tables)	3 Months Ended
Other Expense, Net (Tables)	Mar. 31, 2024
Other Income and Expenses [Abstract]
Schedule of Other (Expense) Income	Other expense, net consisted of the following: Three Months Ended March 31, (DOLLARS IN MILLIONS) 2024 2023 Foreign exchange losses $ (8) $ (15) Interest income 3 — Losses on business divestitures — (14) Pension-related benefit 1 5 Other 3 7 Other expense, net $ (1) $ (17)

Property, Plant, and Equipment

Property, Plant, and Equipment (Tables)	3 Months Ended
Property, Plant, and Equipment (Tables)	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, plant and equipment consisted of the following amounts: (DOLLARS IN MILLIONS) March 31, 2024 December 31, 2023 Asset Type Land $ 192 $ 195 Buildings and improvements 1,805 1,822 Machinery and equipment 3,754 3,752 Information technology 496 473 Construction in process 366 400 Total Property, plant and equipment 6,613 6,642 Accumulated depreciation (2,468) (2,402) Total Property, plant and equipment, net $ 4,145 $ 4,240

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets, Net (Tables)	3 Months Ended
Goodwill and Other Intangible Assets, Net (Tables)	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Movements in Goodwill	Movements in goodwill attributable to each reportable segment for the three months ended March 31, 2024 were as follows: (DOLLARS IN MILLIONS) Nourish Health & Biosciences Scent Pharma Solutions Total Balance at January 1, 2024 $ 3,489 $ 4,391 $ 1,490 $ 1,265 $ 10,635 Foreign exchange (35) (39) (8) (15) (97) Balance at March 31, 2024 $ 3,454 $ 4,352 $ 1,482 $ 1,250 $ 10,538 The goodwill balances at January 1, 2024 and March 31, 2024 included $2.623 billion and $2.250 billion of accumulated impairment related to the Nourish and Health & Biosciences reportable segments, respectively. The accumulated impairment relates to impairment charges recorded in 2023 and 2022.
Schedule of Other Intangible Assets, Net	Other intangible assets, net consisted of the following amounts: March 31, December 31, (DOLLARS IN MILLIONS) 2024 2023 Asset Type Customer relationships $ 8,137 $ 8,211 Technological know-how 2,336 2,355 Trade names & patents 334 337 Other 44 44 Total carrying value 10,851 10,947 Accumulated Amortization Customer relationships (1,708) (1,619) Technological know-how (863) (813) Trade names & patents (123) (117) Other (41) (41) Total accumulated amortization (2,735) (2,590) Other intangible assets, net $ 8,116 $ 8,357
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Amortization expense for the next five years, based on valuations and determinations of useful lives, is expected to be as follows: (DOLLARS IN MILLIONS) Remainder of 2024 2025 2026 2027 2028 Estimated future intangible amortization expense $ 502 $ 668 $ 666 $ 573 $ 559

Other Assets and Liabilities,_2

Other Assets and Liabilities, Current and Noncurrent (Tables)	3 Months Ended
	Mar. 31, 2024
Other Assets [Abstract]
Schedule of Other Assets	Other assets consisted of the following amounts: (DOLLARS IN MILLIONS) March 31, 2024 December 31, 2023 Deferred income taxes $ 253 $ 278 Overfunded pension plans 142 139 Cash surrender value of life insurance contracts 50 49 Finance lease right-of-use assets 26 26 Equity method investments 11 11 Other (1) 255 261 Total $ 737 $ 764 _______________________ (1) Includes land usage rights in China, long-term deposits and receivables on certain derivative instruments.
Schedule of Other Current Assets	Prepaid expenses and other current assets consisted of the following amounts: (DOLLARS IN MILLIONS) March 31, 2024 December 31, 2023 Value-added tax receivable $ 171 $ 187 Prepaid income taxes 163 178 Packaging materials and supplies 161 161 Prepaid expenses 202 184 Other 74 165 Total $ 771 $ 875
Other Current Liabilities	Other current liabilities consisted of the following amounts: (DOLLARS IN MILLIONS) March 31, 2024 December 31, 2023 Rebates and incentives payable $ 102 $ 105 Value-added tax payable 49 77 Interest payable 80 65 Current pension and other postretirement benefit obligation 14 13 Accrued insurance (including workers’ compensation) 9 9 Earn outs payable 32 32 Accrued restructuring 3 14 Current operating lease obligation 91 85 Accrued freight 13 14 Accrued commissions payable 11 10 Accrued income taxes 126 194 Accrued expenses payable 300 262 Other 126 97 Total $ 956 $ 977

Debt (Tables)

Debt (Tables)	3 Months Ended
Debt (Tables)	Mar. 31, 2024
Debt Disclosure [Abstract]
Components of Debt	Debt consisted of the following: (DOLLARS IN MILLIONS) Effective Interest Rate March 31, 2024 December 31, 2023 2024 Euro Notes (1) 1.88 % $ — $ 552 2025 Notes (1) 1.22 % 1,000 1,000 2026 Euro Notes (1) 1.93 % 861 879 2027 Notes (1) 1.56 % 1,211 1,212 2028 Notes (1) 4.57 % 398 398 2030 Notes (1) 2.21 % 1,508 1,508 2040 Notes (1) 3.04 % 772 773 2047 Notes (1) 4.44 % 495 495 2048 Notes (1) 5.12 % 787 787 2050 Notes (1) 3.21 % 1,569 1,569 2024 Term Loan Facility (2) 3.75 % — 270 2026 Term Loan Facility (2) 5.82 % 609 625 Revolving Credit Facility (3) 250 — Commercial paper (4) 836 — Bank overdrafts and other 2 3 Total debt 10,298 10,071 Less: Short-term borrowings (5) (1,148) (885) Total Long-term debt $ 9,150 $ 9,186 _______________________ (1) Amount is net of unamortized discount and debt issuance costs. (2) Amount is recorded at fair value. (3) The interest rate on the Revolving Credit Facility is, at the applicable borrower’s option, a per annum rate equal to either (x) an eurocurrency rate plus an applicable margin varying from 1.125% to 1.750% or (y) a base rate plus an applicable margin varying from 0.125% to 0.750%, in each case depending on the public debt ratings for non-credit enhanced long-term senior unsecured debt issued by the Company. (4) The effective interest rate of commercial paper issuances fluctuates as short-term interest rates and demand fluctuate, and deferred debt issuance costs are immaterial. Additionally, the effective interest rate of commercial paper is not meaningful as issuances do not materially differ from short-term interest rates. (5) Includes bank borrowings, commercial paper, overdrafts and current portion of long-term debt.

Leases (Tables)

Leases (Tables)	3 Months Ended
Leases (Tables)	Mar. 31, 2024
Leases [Abstract]
Lease cost and other information	The components of lease expense were as follows: Three Months Ended Three Months Ended (DOLLARS IN MILLIONS) March 31, 2024 March 31, 2023 Operating leases Operating lease cost $ 32 $ 33 Variable lease cost 16 16 Total operating lease cost $ 48 $ 49 Finance leases Finance lease cost $ 3 $ 2 Supplemental cash flow information related to leases was as follows: Three Months Ended Three Months Ended (DOLLARS IN MILLIONS) March 31, 2024 March 31, 2023 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows for operating leases $ 28 $ 33 Financing cash flows for finance leases 2 2 Right-of-use assets obtained in exchange for lease obligations Operating leases 39 137 Finance leases 3 2

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
Financial Instruments (Tables)	Mar. 31, 2024
Investments, All Other Investments [Abstract]
Carrying Amount and Estimated Fair Values of Financial Instruments	The carrying values and the estimated fair values of financial instruments at March 31, 2024 and December 31, 2023 consisted of the following: March 31, 2024 December 31, 2023 (DOLLARS IN MILLIONS) Carrying Value Fair Value Carrying Value Fair Value LEVEL 1 Cash and cash equivalents (1) $ 732 $ 732 $ 703 $ 703 LEVEL 2 Credit facilities and bank overdrafts (2) 252 252 3 3 Derivatives Derivative assets (3) 1 1 41 41 Derivative liabilities (3) 166 166 165 165 Commercial paper (2) 836 836 — — Long-term debt: 2024 Euro Notes (4) — — 552 549 2025 Notes (4) 1,000 937 1,000 924 2026 Euro Notes (4) 861 825 879 835 2027 Notes (4) 1,211 1,066 1,212 1,049 2028 Notes (4) 398 388 398 389 2030 Notes (4) 1,508 1,248 1,508 1,240 2040 Notes (4) 772 535 773 536 2047 Notes (4) 495 389 495 382 2048 Notes (4) 787 687 787 678 2050 Notes (4) 1,569 1,002 1,569 1,029 2024 Term Loan Facility (5) — — 270 270 2026 Term Loan Facility (5) 609 609 625 625 _______________________ (1) The carrying amount of cash and cash equivalents approximates fair value due to the short maturity of those instruments. (2) The carrying amount approximates fair value as the interest rate is reset frequently based on current market rates as well as the short maturity of those instruments. (3) The carrying amount approximates fair value as the instruments are marked-to-market and held at fair value on the Consolidated Balance Sheets. (4) The fair value of the Note is obtained from pricing services engaged by the Company, and the Company receives one price for each security. The fair value provided by the pricing services are estimated using pricing models, where the inputs to those models are based on observable market inputs or recent trades of similar securities. The inputs to the valuation techniques applied by the pricing services are typically benchmark yields, benchmark security prices, credit spreads, reported trades and broker-dealer quotes, all with reasonable levels of transparency. (5) The carrying amount approximates fair value as the Term Loans were assumed at fair value and the interest rate is reset frequently based on current market rates.
Derivative Instruments Notional Amount Outstanding	The following table shows the notional amount of the Company’s derivative instruments outstanding as of March 31, 2024 and December 31, 2023: (DOLLARS IN MILLIONS) March 31, 2024 December 31, 2023 Foreign currency contracts (1) $ (2,697) $ (1,400) Commodity contracts (1) 6 7 Cross currency swaps 1,400 1,400 _______________________ (1) Foreign currency contracts and commodity contracts are presented net of contracts bought and sold.
Derivative Instruments Measured at Fair Value	The following tables show the Company’s derivative instruments measured at fair value (Level 2 of the fair value hierarchy), as reflected on the Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023: March 31, 2024 (DOLLARS IN MILLIONS) Fair Value of Fair Value of Total Fair Value Derivative assets (1) Foreign currency contracts $ — $ 1 $ 1 Total derivative assets $ — $ 1 $ 1 Derivative liabilities (2) Foreign currency contracts $ — $ 33 $ 33 Cross currency swaps 132 — 132 Commodity contracts 1 — 1 Total derivative liabilities $ 133 $ 33 $ 166 December 31, 2023 (DOLLARS IN MILLIONS) Fair Value of Fair Value of Total Fair Value Derivative assets (1) Foreign currency contracts $ — $ 41 $ 41 Total derivative assets $ — $ 41 $ 41 Derivative liabilities (2) Foreign currency contracts $ — $ 4 $ 4 Cross currency swaps 161 — 161 Total derivative liabilities $ 161 $ 4 $ 165 _______________________ (1) Derivative assets are recorded to Prepaid expenses and other current assets on the Consolidated Balance Sheets. (2) Derivative liabilities are recorded to Other current liabilities and Other liabilities on the Consolidated Balance Sheets.
Derivative Instruments Which Were Not Designated as Hedging Instruments	The following table shows the effect of the Company’s derivative instruments which were not designated as hedging instruments on the Consolidated Statements of Income (Loss) and Comprehensive (Loss) Income for the three months ended March 31, 2024 and 2023: Amount of Gain (Loss) Location of Gain (Loss) Recognized in Income on Derivative (DOLLARS IN MILLIONS) Three Months Ended March 31, 2024 2023 Foreign currency contracts (1) $ (3) $ — Other expense, net _______________________ (1) The foreign currency contract net gains (losses) offset any recognized gains (losses) arising from the revaluation of the related intercompany loans during the same respective periods.
Derivative Instruments Designated as Cash Flow and Net Investment Hedging Instruments	The following table shows the effect of the Company’s derivative and non-derivative instruments designated as cash flow and net investment hedging instruments, net of tax, on the Consolidated Statements of Income (Loss) and Comprehensive (Loss) Income for the three months ended March 31, 2024 and 2023: Amount of Gain (Loss) Location of Gain (Loss) Amount of Gain (Loss) Three Months Ended March 31, Three Months Ended March 31, (DOLLARS IN MILLIONS) 2024 2023 2024 2023 Derivatives in Cash Flow Hedging Relationships: Foreign currency contracts $ (7) $ — N/A $ — $ — Derivatives in Net Investment Hedging Relationships: Cross currency swaps 23 (3) N/A — — Non-Derivatives in Net Investment Hedging Relationships: 2024 Euro Notes 3 (9) N/A — — 2026 Euro Notes 15 (14) N/A — — Total $ 34 $ (26) $ — $ —

Discontinued Operations and D_2

Discontinued Operations and Disposal Groups (Tables)	3 Months Ended
Discontinued Operations and Disposal Groups (Tables)	Mar. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations	Included in the Company’s Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023 are the following carrying amounts of the assets and liabilities held for sale: (DOLLARS IN MILLIONS) March 31, 2024 December 31, 2023 Assets Cash and cash equivalents $ 32 $ 26 Trade receivables, net 18 15 Inventories 17 18 Property, plant and equipment, net 7 7 Goodwill 271 276 Other intangible assets, net 144 146 Operating lease right-of-use assets 10 9 Other assets 10 9 Total assets held-for-sale $ 509 $ 506 Liabilities Accounts payable $ 5 $ 4 Deferred tax liability 24 24 Other liabilities 17 18 Total liabilities held-for-sale $ 46 $ 46

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	3 Months Ended
Accumulated Other Comprehensive Income (Loss) (Tables)	Mar. 31, 2024
Equity [Abstract]
Schedule of Changes in Accumulated Other Comprehensive Income (Loss)	The following tables present changes in the accumulated balances for each component of other comprehensive (loss) income, including current period other comprehensive (loss) income and reclassifications out of accumulated other comprehensive loss: (DOLLARS IN MILLIONS) Foreign Gains (Losses) Pension and Total Accumulated other comprehensive (loss) income, net of tax, as of January 1, 2024 $ (1,652) $ 1 $ (245) $ (1,896) OCI before reclassifications (293) (7) 3 (297) Amounts reclassified from AOCI — — 2 2 Net current period other comprehensive income (loss) (293) (7) 5 (295) Accumulated other comprehensive (loss) income, net of tax, as of March 31, 2024 $ (1,945) $ (6) $ (240) $ (2,191) (DOLLARS IN MILLIONS) Foreign Gains (Losses) Pension and Total Accumulated other comprehensive (loss) income, net of tax, as of January 1, 2023 $ (2,066) $ 1 $ (133) $ (2,198) OCI before reclassifications 284 — (1) 283 Amounts reclassified from AOCI — — (1) (1) Net current period other comprehensive income (loss) 284 — (2) 282 Accumulated other comprehensive (loss) income, net of tax, as of March 31, 2023 $ (1,782) $ 1 $ (135) $ (1,916)
Reclassifications of Accumulated Other Comprehensive Income to Consolidated Statement of Comprehensive Income	The following table provides details about reclassifications out of Accumulated other comprehensive loss to the Consolidated Statements of Income (Loss) and Comprehensive (Loss) Income: Three Months Ended March 31, Affected Line Item in the Consolidated Statements of Income (Loss) and Comprehensive (Loss) Income (DOLLARS IN MILLIONS) 2024 2023 Gains (losses) on pension and postretirement liability adjustments Prior service cost $ 1 $ 1 (1) Actuarial losses (3) — (1) Tax — — Provision for income taxes Total $ (2) $ 1 Total, net of income taxes _______________________ (1) The amortization of prior service cost and actuarial loss is included in the computation of net periodic benefit cost. Refer to Note 15 of the Company’s 2023 Form 10-K for additional information regarding net periodic benefit cost.

Nature of Operations and Summ_4

Nature of Operations and Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Interest expense	$ 83,000,000	$ 100,000,000
Other income, net	1,000,000	17,000,000
Receivables factored	406,000,000	402,000,000
Payments to participate in factoring receivable program	6,000,000	5,000,000
Trade receivables	1,977,000,000		$ 1,726,000,000
Trade receivables allowances	$ 37,000,000		52,000,000
Percentage of outstanding receivables by over 365 days	1%
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents	$ 32,000,000	4,000,000	26,000,000	$ 52,000,000
Net Cash Provided by (Used in) Operating Activities	99,000,000	127,000,000
Cash, cash equivalents and restricted cash	771,000,000	617,000,000	735,000,000	$ 552,000,000
Operating lease right-of-use assets	699,000,000		689,000,000
Operating lease liability	651,000,000		642,000,000
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	39,000,000	137,000,000
Other assets	737,000,000		764,000,000
Other liabilities	527,000,000		560,000,000
Accumulated other comprehensive loss	(2,191,000,000)		(1,896,000,000)
Raw materials	728,000,000		779,000,000
Work in process	432,000,000		406,000,000
Finished goods	1,251,000,000		1,292,000,000
Inventories	2,411,000,000		2,477,000,000
Interest Costs Capitalized	4,000,000	4,000,000
Supplier Finance Program, Obligation	0		0
Previously Reported
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Interest expense		111,000,000
Other income, net		6,000,000
Receivables factored		445,000,000
Trade Accounts Receivable With The Company's Own Factoring Agreements
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Receivables factored	191,000,000	$ 197,000,000
Accounts receivable, factoring receivable program, maximum amount	300,000,000
Accounts Receivable, Held-for-sale	$ 178,000,000		$ 196,000,000

Nature of Operations and Summ_5

Nature of Operations and Summary of Significant Accounting Policies - Reconciliation of Cash (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Cash and cash equivalents	$ 732	$ 703	$ 590	$ 483
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents	32	26	4	52
Restricted cash	7	6	16	10
Restricted cash included in Other assets	0	0	7	7
Cash, cash equivalents and restricted cash	$ 771	$ 735	$ 617	$ 552

Nature of Operations and Summ_6

Nature of Operations and Summary of Significant Accounting Policies - Schedule of Bad Debt Reserve (Details) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance at January 1, 2024	$ 52
Bad debt expense	(5)
Write-offs	(9)
Foreign exchange	(1)
Balance at March 31, 2024	37
EGYPT
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Bad debt expense	$ 7

Net Income Per Share - Reconcil

Net Income Per Share - Reconciliation of Shares Used in Computation of Basic and Diluted Net Income Per Share (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income (loss) available to IFF shareholders	$ 60	$ (9)
Weighted average common shares outstanding (basic) (in shares)	255,000,000	255,000,000
Weighted average shares assuming dilution (diluted) (in shares)	256,000,000	255,000,000
Net income per share - basic (in dollars per share)	$ 0.23	$ (0.04)
Net income per share - diluted (in dollars per share)	$ 0.23	$ (0.04)
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		300,000
Stock options and restricted stock awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Adjustment for assumed dilution (in shares)	1,000,000	0

Net Income Per Share - Addition

Net Income Per Share - Additional Information (Detail) - $ / shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dividends declared per share, in dollars per share	$ 0.40	$ 0.81
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		300,000
Participating Securities, Distributed and Undistributed Earnings (Loss), Difference Between Basic Net Income (Loss) Per Share	0	$ 0
Participating Securities, Distributed and Undistributed Earnings (Loss), Difference Between Diluted Net Income (Loss) Per Share	$ 0.01	$ 0
Share Equivalents
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	300,000	400,000

Business Divestiture - Narrativ

Business Divestiture - Narrative (Details) - USD ($) $ in Millions		3 Months Ended
	Apr. 02, 2024	Mar. 31, 2024	Mar. 31, 2023	Mar. 19, 2024
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture of business		$ 37	$ 1
Pharma Solutions \| Maximum
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Fair value of sale consideration				$ 2,850
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations \| Savory Solutions Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal, pretax loss			10
Disposal, tax effect			$ 2
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations \| Cosmetic Ingredients \| Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture of business	$ 841

Restructuring and Other Charg_3

Restructuring and Other Charges, Net - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($) position Position	Mar. 31, 2023 USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 3	$ 52
Additional Charges (Reversals), Net	3
Nutrition & Biosciences, Inc
Restructuring Cost and Reserve [Line Items]
Additional Charges (Reversals), Net	$ 2
Number of positions eliminated \| Position	215
Restructuring and Related Cost, Cost Incurred to Date	$ 49
2023 Restructuring Program
Restructuring Cost and Reserve [Line Items]
Severance costs	$ 1
Number of positions eliminated \| position	670
Restructuring and Related Cost, Cost Incurred to Date	$ 71
Employee Severance \| 2023 Restructuring Program
Restructuring Cost and Reserve [Line Items]
Additional Charges (Reversals), Net	1
Other \| Nutrition & Biosciences, Inc
Restructuring Cost and Reserve [Line Items]
Additional Charges (Reversals), Net	$ 2

Restructuring and Other Charg_4

Restructuring and Other Charges, Net - Changes in Employee-Related Restructuring Liabilities (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 14
Additional Charges (Reversals), Net	3
Non-Cash Charges	(2)
Additional charges, net	3	$ 52
Payments	(12)
Ending Balance	3
Nutrition & Biosciences, Inc
Restructuring Reserve [Roll Forward]
Additional Charges (Reversals), Net	2
Other \| Nutrition & Biosciences, Inc
Restructuring Reserve [Roll Forward]
Beginning Balance	0
Additional Charges (Reversals), Net	2
Non-Cash Charges	(2)
Payments	0
Ending Balance	0
2023 Restructuring Program \| Employee Severance
Restructuring Reserve [Roll Forward]
Beginning Balance	14
Additional Charges (Reversals), Net	1
Non-Cash Charges	0
Payments	(12)
Ending Balance	3
Nourish
Restructuring Reserve [Roll Forward]
Additional charges, net	2	30
Scent
Restructuring Reserve [Roll Forward]
Additional charges, net	0	10
Health & Biosciences
Restructuring Reserve [Roll Forward]
Additional charges, net	1	10
Pharma Solutions
Restructuring Reserve [Roll Forward]
Additional charges, net	$ 0	$ 2

Stock Compensation Plans - Stoc

Stock Compensation Plans - Stock-Based Compensation Expense and Related Tax Benefits (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 19	$ 12
Less: Tax benefit	(4)	(2)
Total stock-based compensation expense, after tax	15	10
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	64
Equity-based awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	18	12
Liability-based awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 1	$ 0

Segment Information - Additiona

Segment Information - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($) segment	Mar. 31, 2023 USD ($)
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of segments \| segment	4
Business divestiture costs	$ 56	$ 21
Integration-related costs	$ 2	$ 10
Net sales attributed to all foreign countries \| Sales \| Customer Concentration Risk
Revenues from External Customers and Long-Lived Assets [Line Items]
Maximum percentage of total consolidated net sales attributed to any non-U.S. country	10%	10%

Segment Information - Reportabl

Segment Information - Reportable Segment Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net sales:
Net sales	$ 2,899	$ 3,027
Segment Adjusted Operating EBITDA:
Adjusted Operating EBITDA	578	503
Other Depreciation and Amortization	278	276
Interest expense	(83)	(100)
Other income, net	(1)	(17)
Restructuring and other charges, net	(3)	(52)
Acquisition, divestiture, and integration related costs	58	31
Tax realignment costs	(1)	0
Strategic initiative costs	(4)	(13)
Regulatory costs	(35)	(5)
Other gains (losses)	0	(5)
Income before taxes	115	14
Business divestiture costs	(56)	(21)
Integration-related costs	(2)	(10)
Nourish
Segment Adjusted Operating EBITDA:
Restructuring and other charges, net	(2)	(30)
Health & Biosciences
Segment Adjusted Operating EBITDA:
Restructuring and other charges, net	(1)	(10)
Scent
Segment Adjusted Operating EBITDA:
Restructuring and other charges, net	0	(10)
Pharma Solutions
Segment Adjusted Operating EBITDA:
Restructuring and other charges, net	0	(2)
Operating Segments \| Nourish
Net sales:
Net sales	1,496	1,653
Segment Adjusted Operating EBITDA:
Segment Adjusted Operating EBITDA	216	208
Operating Segments \| Health & Biosciences
Net sales:
Net sales	531	513
Segment Adjusted Operating EBITDA:
Segment Adjusted Operating EBITDA	159	131
Operating Segments \| Scent
Net sales:
Net sales	645	608
Segment Adjusted Operating EBITDA:
Segment Adjusted Operating EBITDA	157	105
Operating Segments \| Pharma Solutions
Net sales:
Net sales	227	253
Segment Adjusted Operating EBITDA:
Segment Adjusted Operating EBITDA	$ 46	$ 59

Segment Information Segment Inf

Segment Information Segment Information - Net Sales by Destination of Product Delivery (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 2,899	$ 3,027
Europe, Africa and Middle East
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	977	1,070
Greater Asia
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	682	688
North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	866	905
Latin America
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	374	364
Geographic Concentration Risk \| Net sales related to the U.S.
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	811	871
Geographic Concentration Risk \| Net sales attributed to all foreign countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 2,088	$ 2,156
Customer Concentration Risk \| Net sales attributed to all foreign countries \| Sales
Revenues from External Customers and Long-Lived Assets [Line Items]
Maximum percentage of total consolidated net sales attributed to any non-U.S. country	10%	10%

Employee Benefits - Pension and

Employee Benefits - Pension and Other Defined Contribution Retirement Plan Expenses (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit (income) cost	$ (1)	$ (5)
Pension Plans \| U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Interest cost on projected benefit obligation	6	7
Expected return on plan assets	(6)	(8)
Net amortization and deferrals	1	0
Net periodic benefit (income) cost	1	(1)
Pension Plans \| Non-U.S. Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost for benefits earned	6	5
Interest cost on projected benefit obligation	9	9
Expected return on plan assets	(13)	(12)
Net amortization and deferrals	2	0
Net periodic benefit (income) cost	4	$ 2
Contribution to the plans	$ 6

Employee Benefits - Additional

Employee Benefits - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]
Assets for Plan Benefits, Defined Benefit Plan	$ 142,000,000	$ 139,000,000
Defined Contribution and Other Retirement Plans
Defined Benefit Plan Disclosure [Line Items]
Expected contribution to the plan	4,000,000
Contribution to the plans	1,000,000
U.S. Plans \| Qualified Plan
Defined Benefit Plan Disclosure [Line Items]
Contribution to the plans	0
U.S. Plans \| Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Expected contribution to the plan	5,000,000
U.S. Plans \| Nonqualified Plan
Defined Benefit Plan Disclosure [Line Items]
Contribution to the plans	1,000,000
Non-U.S. Plans \| Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Expected contribution to the plan	23,000,000
Contribution to the plans	$ 6,000,000

Employee Benefits - Postretirem

Employee Benefits - Postretirement Benefits Other Than Pension Expenses (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit (income) cost	$ (1)	$ (5)
Defined Contribution and Other Retirement Plans
Defined Benefit Plan Disclosure [Line Items]
Interest cost on projected benefit obligation	1	1
Net amortization and deferrals	(1)	(1)
Net periodic benefit (income) cost	$ 0	$ 0

Other Expense, Net (Details)

Other Expense, Net (Details) - USD ($) $ in Millions	3 Months Ended
Other Expense, Net (Details) - USD ($) $ in Millions	Mar. 31, 2024	Mar. 31, 2023
Other Income and Expenses [Abstract]
Foreign exchange (losses) gains	$ (8)	$ (15)
Interest income	3	0
(Losses) gains on business divestitures	0	(14)
Pension-related benefit	1	5
Other	3	7
Other (expense) income, net	$ (1)	$ (17)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)
Income Taxes [Line Items]
Effective tax rate	47%
Foreign Tax Authority
Income Taxes [Line Items]
Provision for uncertain tax positions	$ 176
Deferred Tax Liabilities, Deemed Repatriation	0
Domestic Tax Authority
Income Taxes [Line Items]
Deferred Tax Liabilities, Deemed Repatriation	174
Other Liabilities
Income Taxes [Line Items]
Unrecognized tax benefits that would impact effective tax rate	128
Accrued interest and penalties	$ 48

Property, Plant, and Equipmen_2

Property, Plant, and Equipment (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Depreciation	$ 110	$ 105
Property, plant and equipment, at cost	6,613		$ 6,642
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(2,468)		(2,402)
Property, plant and equipment, net	4,145		4,240
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	6,613		6,642
Land
Property, Plant and Equipment [Abstract]
Property, plant and equipment, at cost	192		195
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	192		195
Building and Building Improvements
Property, Plant and Equipment [Abstract]
Property, plant and equipment, at cost	1,805		1,822
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	1,805		1,822
Machinery and Equipment
Property, Plant and Equipment [Abstract]
Property, plant and equipment, at cost	3,754		3,752
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	3,754		3,752
Technology Equipment
Property, Plant and Equipment [Abstract]
Property, plant and equipment, at cost	496		473
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	496		473
Construction in Progress
Property, Plant and Equipment [Abstract]
Property, plant and equipment, at cost	366		400
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	$ 366		$ 400

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets, Net - Movements in Goodwill (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Goodwill [Roll Forward]
Goodwill, Beginning Balance	$ 10,635
Foreign exchange	(97)
Balance at March 31, 2024	10,538
Nourish
Goodwill [Roll Forward]
Goodwill, Beginning Balance	3,489
Foreign exchange	(35)
Balance at March 31, 2024	3,454
Goodwill, Impaired, Accumulated Impairment Loss	2,623	$ 2,623
Health & Biosciences
Goodwill [Roll Forward]
Goodwill, Beginning Balance	4,391
Foreign exchange	(39)
Balance at March 31, 2024	4,352
Goodwill, Impaired, Accumulated Impairment Loss	2,250	$ 2,250
Scent
Goodwill [Roll Forward]
Goodwill, Beginning Balance	1,490
Foreign exchange	(8)
Balance at March 31, 2024	1,482
Pharma Solutions
Goodwill [Roll Forward]
Goodwill, Beginning Balance	1,265
Foreign exchange	(15)
Balance at March 31, 2024	$ 1,250

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets, Net - Schedule of Other Intangible Assets, Net (Detail) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Total carrying value	$ 10,851	$ 10,947
Total accumulated amortization	(2,735)	(2,590)
Other intangible assets, net	8,116	8,357
Other Intangible Assets, Net	8,116	8,357
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Total carrying value	8,137	8,211
Total accumulated amortization	(1,708)	(1,619)
Technological know-how
Finite-Lived Intangible Assets [Line Items]
Total carrying value	2,336	2,355
Total accumulated amortization	(863)	(813)
Trade names & patents
Finite-Lived Intangible Assets [Line Items]
Total carrying value	334	337
Total accumulated amortization	(123)	(117)
Other
Finite-Lived Intangible Assets [Line Items]
Total carrying value	44	44
Total accumulated amortization	$ (41)	$ (41)

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets, Net - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Goodwill [Line Items]
Goodwill	$ 10,538		$ 10,635
Amortization of acquisition-related intangibles	168	$ 171
Health & Biosciences
Goodwill [Line Items]
Goodwill	4,352		4,391
Goodwill, Impaired, Accumulated Impairment Loss	2,250		2,250
Goodwill, Impaired, Accumulated Impairment Loss	$ 2,250		$ 2,250

Goodwill and Other Intangible_6

Goodwill and Other Intangible Assets, Net - Future Estimated Amortization Expense (Details) $ in Millions	Mar. 31, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 502
2025	668
2026	666
2027	573
2028	$ 559

Other Assets and Liabilities,_3

Other Assets and Liabilities, Current and Noncurrent - Schedule of Other Assets (Detail) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Other Assets [Abstract]
Finance lease right-of-use assets	$ 26	$ 26
Deferred Income Taxes and Other Assets, Noncurrent	253	278
Overfunded pension plans	142	139
Cash surrender value of life insurance contracts	50	49
Other	255	261
Total	737	764
Value Added Tax Receivable, Current	171	187
Income Taxes Receivable, Current	163	178
Prepaid Supplies	161	161
Prepaid Expense, Current	202	184
Assets held for sale	509	506
Accounts and Other Receivables, Net, Current	74	165
Prepaid expenses and other current assets	771	875
Sales and Excise Tax Payable, Current	49	77
Interest Payable, Current	80	65
Liability, Pension and Other Postretirement and Postemployment Benefits, Current	14	13
Accrued Insurance, Current	9	9
Earn Outs Payable, Current	32	32
Restructuring Reserve	3	14
Other current liabilities	91	85
Accrued Freight, Current	13	14
Accrued Commissions Payable, Current	11	10
Accrued Income Taxes, Current	126	194
Liabilities held for sale	46	46
Other Accounts Payable and Accrued Liabilities	300	262
Other Sundry Liabilities, Current	126	97
Other current liabilities	956	977
Rebates and Incentives Payable, Current	102	105
Equity method investment	$ 11	$ 11
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other current liabilities	Other current liabilities

Debt - Components of Debt (Deta

Debt - Components of Debt (Detail) - USD ($) $ in Millions	Jul. 28, 2021	Mar. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Commercial paper		$ 836	$ 0
Total debt		10,298	10,071
Less: Short term borrowings		(1,148)	(885)
Total Long-term debt		$ 9,150	9,186
Revolving Credit Facility \| Minimum \| Base rate \| Citibank, N.A.
Debt Instrument [Line Items]
Applicable margin on variable rate, percent	0.125%
Revolving Credit Facility \| Minimum \| Eurocurrency Rate \| Citibank, N.A.
Debt Instrument [Line Items]
Applicable margin on variable rate, percent	1.125%
Revolving Credit Facility \| Maximum \| Base rate \| Citibank, N.A.
Debt Instrument [Line Items]
Applicable margin on variable rate, percent	0.75%
Revolving Credit Facility \| Maximum \| Eurocurrency Rate \| Citibank, N.A.
Debt Instrument [Line Items]
Applicable margin on variable rate, percent	1.75%
2024 Euro Notes \| Loans payable
Debt Instrument [Line Items]
Effective Interest Rate		1.88%
Senior notes, current		$ 0	552
2025 Notes \| Loans payable
Debt Instrument [Line Items]
Effective Interest Rate		1.22%
Senior notes, noncurrent		$ 1,000	1,000
2026 Euro Notes \| Loans payable
Debt Instrument [Line Items]
Effective Interest Rate		1.93%
Senior notes, noncurrent		$ 861	879
2027 Notes \| Loans payable
Debt Instrument [Line Items]
Effective Interest Rate		1.56%
Senior notes, noncurrent		$ 1,211	1,212
2028 Notes \| Loans payable
Debt Instrument [Line Items]
Effective Interest Rate		4.57%
Senior notes, noncurrent		$ 398	398
2030 Notes \| Loans payable
Debt Instrument [Line Items]
Effective Interest Rate		2.21%
Senior notes, noncurrent		$ 1,508	1,508
2040 Notes \| Loans payable
Debt Instrument [Line Items]
Effective Interest Rate		3.04%
Senior notes, noncurrent		$ 772	773
2047 Notes \| Loans payable
Debt Instrument [Line Items]
Effective Interest Rate		4.44%
Senior notes, noncurrent		$ 495	495
2048 Notes \| Loans payable
Debt Instrument [Line Items]
Effective Interest Rate		5.12%
Senior notes, noncurrent		$ 787	787
2050 Notes \| Loans payable
Debt Instrument [Line Items]
Effective Interest Rate		3.21%
Senior notes, noncurrent		$ 1,569	1,569
2024 Term Loan Facility \| Loans payable
Debt Instrument [Line Items]
Effective Interest Rate		3.75%
Senior notes, current		$ 0	270
2026 Term Loan Facility \| Loans payable
Debt Instrument [Line Items]
Effective Interest Rate		5.82%
Senior notes, noncurrent		$ 609	625
Bank overdrafts and other
Debt Instrument [Line Items]
Bank overdrafts and other		2	3
Revolving Credit Facility \| Loans payable
Debt Instrument [Line Items]
Long-term line of credit		$ 250	$ 0

Debt - Narrative (Details)

Debt - Narrative (Details) € in Millions, $ in Millions				3 Months Ended
Debt - Narrative (Details) € in Millions, $ in Millions	Apr. 05, 2024 USD ($)	Mar. 14, 2024 EUR (€)	Feb. 01, 2024 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)
Debt Instrument [Line Items]
Proceeds from issuance of commercial paper (maturities after three months)				$ 2,099	$ 1,320
Repayments of commercial paper				1,263	919
Subsequent Event
Debt Instrument [Line Items]
Repayments of commercial paper	$ 586
Revolving Credit Facility \| Citibank, N.A.
Debt Instrument [Line Items]
Proceeds from lines of credit				250	400
Repayments of lines of credit					$ 500
Revolving Credit Facility \| Citibank, N.A. \| Subsequent Event
Debt Instrument [Line Items]
Repayments of lines of credit	$ 250
2024 Term Loan Facility \| Loans payable
Debt Instrument [Line Items]
Repayments of debt			$ 270
2024 Euro Notes \| Loans payable
Debt Instrument [Line Items]
Repayments of debt \| €		€ 500
2026 Term Loan Facility \| Loans payable
Debt Instrument [Line Items]
Repayments of debt				$ 16

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Lessee, Lease, Description [Line Items]
Remaining lease term	50 years
Option to extend lease term	15 years
Operating lease liability	$ 651	$ 642
Operating lease right-of-use assets	699	689
Finance lease right-of-use assets	$ 26	$ 26

Leases - Lease expenses (Detail

Leases - Lease expenses (Details) - USD ($) $ in Millions	3 Months Ended
Leases - Lease expenses (Details) - USD ($) $ in Millions	Mar. 31, 2024	Mar. 31, 2023
Leases [Abstract]
Operating lease cost	$ 32	$ 33
Variable lease cost	16	16
Total operating lease cost	48	49
Finance lease cost	$ 3	$ 2

Leases - Supplemental cash flow

Leases - Supplemental cash flow information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Leases [Abstract]
Operating cash flows for operating leases	$ 28	$ 33
Financing cash flows for finance leases	2	2
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	39	137
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability	$ 3	$ 2

Financial Instruments - Carryin

Financial Instruments - Carrying Amount and Estimated Fair Values of Financial Instruments (Detail) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Other current liabilities	Other current liabilities
Commercial paper	$ 836	$ 0
Reported Value Measurement
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	732	703
Credit facilities and bank overdrafts	252	3
Derivative Asset	1	41
Derivative Liability	166	165
Commercial paper	836	0
Reported Value Measurement \| 2024 Euro Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes, current	0	552
Reported Value Measurement \| 2025 Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes, noncurrent	1,000	1,000
Reported Value Measurement \| 2026 Euro Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes, noncurrent	861	879
Reported Value Measurement \| 2028 Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes, noncurrent	398	398
Reported Value Measurement \| 2048 Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes, noncurrent	787	787
Reported Value Measurement \| 2047 Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes, noncurrent	495	495
Reported Value Measurement \| 2024 Term Loan Facility
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes, current	0	270
Reported Value Measurement \| 2027 Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes, noncurrent	1,211	1,212
Reported Value Measurement \| 2030 Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes, noncurrent	1,508	1,508
Reported Value Measurement \| 2040 Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes, noncurrent	772	773
Reported Value Measurement \| 2050 Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes, noncurrent	1,569	1,569
Reported Value Measurement \| 2026 Term Loan Facility
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes, noncurrent	609	625
Estimate of Fair Value Measurement
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	732	703
Credit facilities and bank overdrafts	252	3
Derivative Asset	1	41
Derivative Liability	166	165
Commercial paper	836	0
Estimate of Fair Value Measurement \| 2024 Euro Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes, current	0	549
Estimate of Fair Value Measurement \| 2025 Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes, noncurrent	937	924
Estimate of Fair Value Measurement \| 2026 Euro Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes, noncurrent	825	835
Estimate of Fair Value Measurement \| 2028 Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes, noncurrent	388	389
Estimate of Fair Value Measurement \| 2048 Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes, noncurrent	687	678
Estimate of Fair Value Measurement \| 2047 Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes, noncurrent	389	382
Estimate of Fair Value Measurement \| 2024 Term Loan Facility
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes, current	0	270
Estimate of Fair Value Measurement \| 2027 Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes, noncurrent	1,066	1,049
Estimate of Fair Value Measurement \| 2030 Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes, noncurrent	1,248	1,240
Estimate of Fair Value Measurement \| 2040 Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes, noncurrent	535	536
Estimate of Fair Value Measurement \| 2050 Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes, noncurrent	1,002	1,029
Estimate of Fair Value Measurement \| 2026 Term Loan Facility
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Senior notes, noncurrent	$ 609	$ 625

Financial Instruments - Additio

Financial Instruments - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($) swap	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)
Derivative [Line Items]
Fair value of derivative liabilities	$ 166		$ 165
Fair value of derivative assets	1		41
Derivative, Net Hedge Ineffectiveness Gain (Loss)	4	$ 4
Cross currency swaps
Derivative [Line Items]
Derivative instruments outstanding	1,400		1,400
Fair value of derivative liabilities	132		161
2022 Cross Currency Swaps \| Net Investment Hedging
Derivative [Line Items]
Derivative instruments outstanding	1,400
Designated as Hedging Instrument
Derivative [Line Items]
Fair value of derivative liabilities	133		161
Fair value of derivative assets	0		0
Designated as Hedging Instrument \| Euro Notes
Derivative [Line Items]
Hedged liability, debt	861
Designated as Hedging Instrument \| Cross currency swaps
Derivative [Line Items]
Fair value of derivative liabilities	$ 132		$ 161
Designated as Hedging Instrument \| 2022 Cross Currency Swaps
Derivative [Line Items]
Number of Foreign Currency Derivatives Held \| swap	12
Derivative Assets (Liabilities), at Fair Value, Net	$ 132

Financial Instruments - Derivat

Financial Instruments - Derivative Instruments Notional Amount Outstanding (Detail) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Foreign currency contracts
Schedule Of Information By Major Category Of Credit Derivatives Contracts [Line Items]
Derivative instruments outstanding, net	$ (2,697)	$ (1,400)
Commodity contracts
Schedule Of Information By Major Category Of Credit Derivatives Contracts [Line Items]
Derivative instruments outstanding, net	6	7
Cross currency swaps
Schedule Of Information By Major Category Of Credit Derivatives Contracts [Line Items]
Derivative instruments outstanding	$ 1,400	$ 1,400

Financial Instruments - Deriv_2

Financial Instruments - Derivative Instruments Measured at Fair Value (Detail) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Derivatives, Fair Value [Line Items]
Fair value of derivative assets	$ 1	$ 41
Fair value of derivative liabilities	166	165
Foreign currency contracts
Derivatives, Fair Value [Line Items]
Fair value of derivative assets	1	41
Fair value of derivative liabilities	33	4
Cross currency swaps
Derivatives, Fair Value [Line Items]
Fair value of derivative liabilities	132	161
Commodity contracts
Derivatives, Fair Value [Line Items]
Fair value of derivative liabilities	1
Fair Value of Derivatives Designated as Hedging Instruments
Derivatives, Fair Value [Line Items]
Fair value of derivative assets	0	0
Fair value of derivative liabilities	133	161
Fair Value of Derivatives Designated as Hedging Instruments \| Foreign currency contracts
Derivatives, Fair Value [Line Items]
Fair value of derivative assets	0	0
Fair value of derivative liabilities	0	0
Fair Value of Derivatives Designated as Hedging Instruments \| Cross currency swaps
Derivatives, Fair Value [Line Items]
Fair value of derivative liabilities	132	161
Fair Value of Derivatives Designated as Hedging Instruments \| Commodity contracts
Derivatives, Fair Value [Line Items]
Fair value of derivative liabilities	1
Fair Value of Derivatives Not Designated as Hedging Instruments
Derivatives, Fair Value [Line Items]
Fair value of derivative assets	1	41
Fair value of derivative liabilities	33	4
Fair Value of Derivatives Not Designated as Hedging Instruments \| Foreign currency contracts
Derivatives, Fair Value [Line Items]
Fair value of derivative assets	1	41
Fair value of derivative liabilities	33	4
Fair Value of Derivatives Not Designated as Hedging Instruments \| Cross currency swaps
Derivatives, Fair Value [Line Items]
Fair value of derivative liabilities	0	$ 0
Fair Value of Derivatives Not Designated as Hedging Instruments \| Commodity contracts
Derivatives, Fair Value [Line Items]
Fair value of derivative liabilities	$ 0

Financial Instruments - Deriv_3

Financial Instruments - Derivative Instruments Which Were Not Designated as Hedging Instruments (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Foreign currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) on derivative, net	$ (3)	$ 0

Financial Instruments - Deriv_4

Financial Instruments - Derivative Instruments Designated Net Investment Hedging Instruments (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in OCI on Derivative and Non-Derivative (Effective Portion)	$ 34	$ (26)
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	0	0
Cross currency swaps \| Derivatives in Net Investment Hedging Relationships
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in OCI on Derivative and Non-Derivative (Effective Portion)	23	(3)
2024 Euro Notes \| Derivatives in Net Investment Hedging Relationships
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in OCI on Derivative and Non-Derivative (Effective Portion)	3	(9)
2026 Euro Notes \| Derivatives in Net Investment Hedging Relationships
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in OCI on Derivative and Non-Derivative (Effective Portion)	15	(14)
Foreign currency contracts \| Derivatives in Cash Flow Hedging Relationships [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in OCI on Derivative and Non-Derivative (Effective Portion)	(7)	0
Foreign currency contracts \| Derivatives in Cash Flow Hedging Relationships [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	$ 0	$ 0

Discontinued Operations and D_3

Discontinued Operations and Disposal Groups (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents	$ 32	$ 26	$ 4	$ 52
Operating lease right-of-use assets	699	689
Disposal Group, Held-for-sale, Not Discontinued Operations \| Cosmetic Ingredients
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents	32	26
Disposal Group, Including Discontinued Operation, Trade Receivables, Net	18	15
Disposal Group, Including Discontinued Operation, Inventory	17	18
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment	7	7
Disposal Group, Including Discontinued Operation, Goodwill	271	276
Disposal Group, Including Discontinued Operation, Intangible Assets	144	146
Operating lease right-of-use assets	10	9
Other assets	10	9
Total assets	509	506
Accounts payable	5	4
Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities	24	24
Other liabilities	17	18
Total liabilities	$ 46	$ 46

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance, beginning of period	$ 14,611
Net current period other comprehensive income (loss)	(295)	$ 282
Balance, end of period	14,291
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance, beginning of period	(1,652)	(2,066)
OCI before reclassifications	(293)	284
Amounts reclassified from AOCI	0	0
Net current period other comprehensive income (loss)	(293)	284
Balance, end of period	(1,945)	(1,782)
Gains (Losses) on Derivatives Qualifying as Hedges
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance, beginning of period	1	1
OCI before reclassifications	(7)	0
Amounts reclassified from AOCI	0	0
Net current period other comprehensive income (loss)	(7)	0
Balance, end of period	(6)	1
Pension and Postretirement Liability Adjustment
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance, beginning of period	(245)	(133)
OCI before reclassifications	3	(1)
Amounts reclassified from AOCI	(2)	1
Net current period other comprehensive income (loss)	5	(2)
Balance, end of period	(240)	(135)
AOCI Attributable to Parent
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance, beginning of period	(1,896)	(2,198)
OCI before reclassifications	(297)	283
Amounts reclassified from AOCI	(2)	1
Net current period other comprehensive income (loss)	(295)	282
Balance, end of period	$ (2,191)	$ (1,916)

Accumulated Other Comprehensi_4

Accumulated Other Comprehensive Income (Loss) - Reclassifications of Accumulated Other Comprehensive Income to Consolidated Statement of Comprehensive Income (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Schedule Of Reclassification Of Accumulated Other Comprehensive Income Loss [Line Items]
Foreign currency contracts	$ 1,875	$ 2,063
Interest Expense	(83)	(100)
Tax	54	22
Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member]
Schedule Of Reclassification Of Accumulated Other Comprehensive Income Loss [Line Items]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	1	1
Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]
Schedule Of Reclassification Of Accumulated Other Comprehensive Income Loss [Line Items]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	(3)	0
Pension and Postretirement Liability Adjustment
Schedule Of Reclassification Of Accumulated Other Comprehensive Income Loss [Line Items]
Tax	0	0
Reclassification out of Accumulated Other Comprehensive Income \| Pension and Postretirement Liability Adjustment
Schedule Of Reclassification Of Accumulated Other Comprehensive Income Loss [Line Items]
Total	$ (2)	$ 1

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Millions			3 Months Ended
	Mar. 11, 2020	Oct. 29, 2019	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Commitments And Contingencies [Line Items]
Bank guarantees related to appeals on income tax and indirect tax cases			$ 10
Bank Guarantees and Standby Letters of Credit, Amount Outstanding			60
Available lines of credit			1,860
Line of Credit Facility, Current Borrowing Amount/Total Amount Drawn Down			1,089
Commercial paper			836		$ 0
Legal and consulting fees			35	$ 5
Bank guarantees and pledged assets to pursue defenses related to other contingencies			18
Revolving Credit Facility \| Loans payable
Commitments And Contingencies [Line Items]
Long-term line of credit			250		$ 0
Pledged assets
Commitments And Contingencies [Line Items]
The amount of pledged assets, principally PP&E to cover income tax and indirect tax assessments			8
Bank Guarantees, Commercial Guarantees, Standby Letters Of Credit and Surety Bonds
Commitments And Contingencies [Line Items]
Bank Guarantees, Commercial Guarantees, Letters Of Credit and Surety Bonds Outstanding			226
Revolving Credit Facility \| Citibank, N.A.
Commitments And Contingencies [Line Items]
Line of credit, current borrowing capacity			$ 1,791
Chief Executive Officer
Commitments And Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense	$ 20	$ 20

Redeemable Noncontrolling Inter

Redeemable Noncontrolling Interests (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Balance at beginning	$ 31
Share of profit or loss attributable to redeemable noncontrolling interests	1	$ 1
Balance at end	$ 35

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Business Acquisition [Line Items]
Goodwill	$ 10,538	$ 10,635
Common stock, par value, in dollars per share	$ 0.125	$ 0.125
Nourish
Business Acquisition [Line Items]
Goodwill	$ 3,454	$ 3,489
Health & Biosciences
Business Acquisition [Line Items]
Goodwill	4,352	4,391
Pharma Solutions
Business Acquisition [Line Items]
Goodwill	1,250	1,265
Scent
Business Acquisition [Line Items]
Goodwill	$ 1,482	$ 1,490

Acquisitions - Schedule of asse

Acquisitions - Schedule of assets acquired and liabilities assumed (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Business Acquisition [Line Items]
Goodwill	$ 10,538	$ 10,635